Design and Development of Colon Specific Delivery Systems of Aceclofenac Tablet by Karthik, Vadlamudi
DESIGN AND DEVELOPMENT OF COLON SPECIFIC
DELIVERY SYSTEMS OF ACECLOFENAC TABLET
 Dissertation Submitted to the
THE TAMILNADU Dr.MGR MEDICAL UNIVERSITY, CHENNAI,
TAMILNADU. 
                  In partial fulfillment of the requirements for the award of degree of
MASTER OF PHARMACY
In
PHARMACEUTICS
By
KARTHIK VADLAMUDI
(Reg. No. 26104504)
UNDER THE GUIDANCE OF
 Mrs. S.L.LAURA KAVIARASU M.Pharm.,
Assistant Professor
Department of Pharmaceutics
K.K COLLEGE OF PHARMACY,
                               GERUGAMBAKKAM, CHENNAI,   600122
                                                 TAMIL NADU                                                        
                                                    MAY 2012
                                            CERTIFICATE
This is to certify that the dissertation entitled  “DESIGN AND DEVELOPMENT
OF  COLON  SPECIFIC  DELIVERY  SYSTEMS  OF  ACECLOFENAC
TABLET”  is a bonafide and genuine research work carried out at the Department
of  Pharmaceutics,  K.K  College  of  pharmacy  by  KARTHIK  VADLAMUDI,
B.Pharm., during the year 2011-2012 under the supervision of Asst. Prof. Mrs.
S.L.LAURA KAVIARASU., This dissertation is submitted for partial fulfillment
of  the  requirements  for  the  award  of  degree  of  Masters  of  Pharmacy
(Pharmaceutics), by the Tamil Nadu Dr. M.G.R Medical University, Chennai-32. 
PRINCIPAL                                         DIRECTOR
Prof. A. MEENA  M.Pharm.,( Ph.D)., Prof. Dr. V.VAIDHYALINGAM. M.Pharm., Ph.D.,
 K.K. College of Pharmacy    K.K. College of Pharmacy
Chennai- 600122                  Chennai-600122
CERTIFICATE
This is to certify that the dissertation entitled “DESIGN AND DEVELOPMENT
OF  COLON  SPECIFIC  DELIVERY  SYSTEMS  OF  ACECLOFENAC
TABLET”  is  a  bonafide  and  genuine  research  work  carried  out  by
Mr. KARTHIK VADLAMUDI during the year 2011-2012 under the supervision
of   Mrs. S.L.LAURA KAVIARASU M.Pharm,, Asst. Professor, Department of
Pharmaceutics,  K.K  College  of  Pharmacy,  Chennai-600122.  This  dissertation
submitted  in  partial  fulfillment  for  the  award  of  degree  of
Master  of  Pharmacy  (Pharmaceutics),  by  The  Tamilnadu  Dr.M.G.R.  Medical
University, Chennai-32.
    
                                          Prof.Dr. K. SENTHILKUMARAN  M.Pharm., Ph.D.,
HEAD OF THE DEPARTMENT,
DEPARTMENT OF PHARMACEUTICS.
                                         K.K. College of Pharmacy,
                                         Chennai – 600122.
CERTIFICATE
This is to certify that the Dissertation entitled “DESIGN AND DEVELOPMENT
OF  COLON  SPECIFIC  DELIVERY  SYSTEMS  OF  ACECLOFENAC
TABLET” is a bonafide and genuine research work carried out at Department of
Pharmaceutics, K.K College of Pharmacy, Chennai-600122, by  Mr. KARTHIK
VADLAMUDI during the year 2011-2012 under my supervision. This Dissertation
submitted in partial  fulfillment for the award of degree of Master of Pharmacy
(Pharmaceutics), by The Tamil Nadu Dr.M.G.R. Medical University, Chennai-32
                                                      SUPERVISOR
  Mrs. S.L. LAURA KAVIARASU. M.Pharm.,
                                                      Asst. Professor, 
                                                      Dept. of Pharmaceutics,
                                                      K.K. College of Pharmacy,
                                                     Chennai-60012
ACKNOWLEDGEMENT
The satisfaction and euphoria that come along with successful completion of any work 
would be incomplete unless we mention the names of the people who made it possible, whose 
constant guidance and encouragement served as a beam of light and crowned out the efforts.
First of all, it is by the love and blessings of God (my parents) that I am able to 
complete my investigation studies successfully and I present this piece of work which I am 
eternally indebted. 
  First and foremost, I wish to express my deepest gratitude to respected Prof. K. R. 
Arumugam, M.Pharm., Chairman, K. K. College of Pharmacy, Chennai for his help and 
support.
         I now take this opportunity to express sincere thanks to Mrs. A. Meena, 
M.Pharm., (Ph.D.,) Principal, K.K. College of Pharmacy, for her support and constant 
encouragement throughout my project work.
          I wish to express my deep gratitude to Prof. Dr. V. Vaidhyalingam, M.Pharm., Ph.D.,
Director, K.K. College of Pharmacy for his hearty cooperation & valuable guidance throughout
these two years of my M.Pharm, course.
I owe a debt of gratitude to Prof. Dr. K. Senthilkumaran, M.Pharm., Ph.D., Head of 
the Department, Department of pharmaceutics, K.K. College of pharmacy, for his valuable 
guidance and providing facilities during the course of my work.
I owe a debt of gratitude to my Research Guide Mrs.S.L. Laura kaviarasu , Asst 
Professor Department of Pharmaceutics for spending her valuable time for giving me 
knowledge, encouragement and successful completion of my research work.  I am deeply 
indebted to the teaching staff of the department who was always a source of knowledge and 
inspiration to me, especially Mrs. Rajarajeswari Hariharan, M.Pharm., 
Ms. P. Kavitha, M.Pharm.,  Mrs. pheebha, M.Pharm., for their prompt assistance and 
cooperative attitude.
I also wish to express my sincere thanks to Mr. S.Rambabu, sir  from (officer  of 
commercial taxses  ) . For his valuable guidance, dynamic approach, innovative advices, 
technical and morale support given to me throughout the course of this dissertation work and 
for granting me the opportunity to do project with his kind support
  I express my special thanks to Mr. V. sundeep kumar,sir  scientist , Mr. G.V.Chandra Shekar 
sir ,scientist  , Mr. Pabhakar sir , scientist  , Ramu sir , scientist  ,Kishan sir, scientist,Koti sir, 
scientist  ,Venu sir scientist  of  Aurobindo pharma Limited ,Hyderabad for their valuable 
advices, morale support and guidance throughout my education. With their dynamic approach 
which boosted my morale, which helped me in completion of this dissertation
I express my special thanks to my friends V.Pavan, G.Sravani,  Aruna, 
Ch.Meenakshi & Venkat & Swapna. . encouragement, moral strength that they 
always showered on me. 
            Thanks for the cheerful company created by my classmates Naresh kumar gupta, Satya 
Naveen, Harinadh, Srikanth, Murali, Azharruddin,Israel prabhu, Swetha and Pratyusha.  
I would like to express my heartfelt gratitude to my father Mr. V.Vijaya 
Saradhi, mother smt .V.Ganga Bhavani ,brother V.Anjani Kumar (M.S,In 
Engineering,Scotland)
The completion of this dissertation is not only fulfillment of my dreams but 
also the dreams of my parents who have taken a lot of pain for me in completion of 
higher studies successfully, whose full hearted co-operation, love and moral support.
Place: CHENNAI                                         Karthik Vadlamudi
Date:                                     
                                                                                        List of abbreviations
LIST OF ABBREVIATIONS USE:
                   Abs Absorbance
                  Conc Concentration
                  CDDS Colon specific drug delivery system
                  DSC Differential Scanning Calorimetry
                  F Formulation
                  FT-IR Fourier-Transform InfraRed
                  g Gram(S)
                  GIT Gastro intestinal tract
                  GMP Good Manufacturing Practice
                  H Hours
                  HCL Hydrochloric acid
                  ICH International Conference on Harmonization
                  IP Indian Pharmacopoeia
                  IBD Inflammatory bowel disease
                  min Minutes
                  mg milligram
                  NSAIDS Non Steroidal Anti-Inflammatory Drugs
                  nm Nanometer
                  RH Relative humidity
                  s Seconds
                  SD Standard deviation 
                 UV Ultraviolet
                 USP United States Pharmacopoeia
                 w/w Weight by weight
                 w/v Weight by volume
                 λmax Lambda max
                µg, mcg Microgram 
k.k college of pharmacy
                                                                                            Table of contents
Chapter No. Title Page No.
1 Introduction 1 - 27
2 Review of Literature 28 - 32
3 Aim & Objective 33
4 Plan of work 34
5 Drug profile 35 - 37
6 Excipient profile 38 - 41
7 Materials 42 – 43
8         Methodology 44 – 53
9 Results 54 – 66
10 Discussion 67 – 68
11 Summary 69
12  Conclusion 70
13            Bibliography
  
71 - 76
TABLE OF CONTENTS
K.K college of pharmacy
                                                                                                      List of Tables
LIST OF TABLES
Table
No.
Title Page
No.
1 Properties of Gastro Intestinal Tract 4
2 Approaches for the development of colon targeted drug delivery 12
3 List of pH dependent polymers 16
4 Materials used in Formulation of CDDS 21
5 Marketed colon specific drug delivery systems 27
6 Threshold pH of Eudragit polymers 40
7 Materials used 42
8 Instruments used 43
9 Carr’s Index and Hausner’s Ratio values 46
10 Pharmacopoeial specifications for tablet weight variation 48
11 Formulation of Aceclofenac tablets (F1 –F5) 50
12 Drug – Exipient Compatibility Studies 54
13 Data obtained from DSC Curves 56
14 Evaluation of Pre-formulation parameters of Aceclofenac tablet
(F1-F5 )
59
15 Evaluation of Post-Compression parameters of Aceclofenac tablets 59
16 Calibration and  absorbance values of Aceclofenac in 7.4 pH phosphate
buffer at 276 nm 
60
17 Determination of λmax of Aceclofenac in 0.1 N Hcl 61
18 Determination of λmax of Aceclofenac in 6.8 pH phosphate buffer 62
Table
No.
Title Page
No.
k.k college of pharmacy
                                                                                                      List of Tables
19 Determination of λmax of Aceclofenac in 7.4 pH phosphate buffer 63
20 Invitro drug release from Aceclofenac formulations (F1-F5) 64
21 Stability  of Aceclofenac Formulation (F4) at 40±2⁰C/75±5%RH 66
22 In vitro drug release of Aceclofenac  (F4) after placing in stability
chamber 
66
k.k college of pharmacy
                                                                                                    List of Figures
LIST OF FIGURES
Figure
No.
Title Page
No.
1 Structure of human GIT 3
2 Structure of colon 4
3 Fate of CDDS Tablet After Administration 7
4 Colonic Diseases 9
5 Prodrugs used for targeted drug delivery to colon 14
6 DSC of Pure drug Aceclofenac 55
7 DSC of polymer Eudragit S100 55
8 DSC of Aceclofenac and Eudragit S100 56
9 FT-IR of Pure Aceclofenac
 
57
10 FT-IR of Aceclofenac& (F4)
 
57
11 Comparison of FT-IR of Pure Aceclofenac and its formulation (F4)
 
58
12 Aceclofenac Standard Calibration curve in 7.4 pH Phosphate buffer
 
60
13 Determination of λmax of Aceclofenac in 0.1 N Hcl 61
k.k college of pharmacy
                                                                                                    List of Figures
Figure
No.
Title Page
No.
14 Determination of λmax of Aceclofenac in 6.8 pH phosphate buffer 62
15 Determination of λmax of Aceclofenac in 7.4 pH phosphate buffer 63
16 In vitro drug release of Aceclofenac( F1 – F5) 65
k.k college of pharmacy
                                                                                            Introduction
         
INTRODUCTION
Among  the  various  routes  of  administration,  the  oral  route  is  considered  to  be  most
convenient for the administration of drugs to patients. On oral administration of conventional
dosage forms drug normally dissolves in the gastro-intestinal fluids and is absorbed from
regions of the gastro-intestinal tract, which depends upon the physicochemical properties of
the drug. It has a serious drawback in conditions where localized delivery of the drug in the
colon  is  required  or  in  conditions  where  a  drug  needs  to  be  protected  from the  hostile
environment of upper GIT. Dosage forms that deliver drugs in the colon rather than upper
GIT has number of advantages. 
Oral delivery of drugs in the colon is valuable in the treatment of diseases of colon where by
high  local  concentration  can  be  achieved  while  minimizing  side  effects.  The  colon  is
attracting of an interest as a site where poorly absorbed drug molecule may have an improved
bioavailability. This region of the colon having a somewhat less hostile environment which is
with less diversity and intensity of activity than the stomach and small intestine. Additionally,
the colon has a long retention time and appears highly responsible to agents that enhance the
absorption of poorly absorbed drugs. 
The simplest method for targeting of drugs to the colon is to obtain slower release rates or
longer release periods by the application of thicker layers of conventional enteric coating or
extremely slow releasing matrices. These delayed mechanisms are designed to improve the
efficacy of the drug by concentrating the drug molecules, where they are needed most and
also minimize the potential side effects and drug instability issues associated with premature
release of drug in the upper parts of the Gastrointestinal tract, namely stomach and small
intestine.  Colon targeted drug delivery would ensures direct  treatment at  the disease site,
lower dosing and less systemic side effects. In addition to restricted therapy, the colon can
also be utilized as a portal for the entry of drugs into the systemic circulation. For example,
molecules  that  are  degraded  or  poorly absorbed  in  the  upper  gut,  such  as  peptides  and
proteins, may be better absorbed from the more beign environment of the colon. 
There is  less free fluid in the colon than in the small intestine and hence, dissolution could be
problematic  for  poorly water-soluble  drugs.  In  such  instances,  the  drug  may be  need  to
delivered in a presolubilized form or delivery should be directed to the proximal colon, as a
fluid gradient exists in the colon with more free water present in the proximal colon than in
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the  distal  colon.  Aside  from  drug  solubility,  the  stability  of  the  drug  in  the  colonic
environment is a further factor that warrants attention. The drug could bind in a nonspecific
manner  to  dietary residues,  intestinal  secretions,  mucus  or  general  faecal  matter,  thereby
reducing the concentration of free drug. Moreover, the resident microflora could also affect
colonic performance via degradation of the drug.
HISTORY:
In  1942,  Svartz  discovered  that  sulfasalazine;  the  sulfanilamide  prodrug  of  5-
aminosalicylicacid (5-ASA) is  effective in  the treatment  of  rheumatoid arthritis  and anti-
inflammatory disease.  The exact  modes by which the drug target  itself  to  the colon was
elucidated much latter in 1970 i.e., colon specific azo-reductase splits sulfasalazine causing
the release  of  the  active moiety 5-  aminosalicylicacid.  After  the  several  other  azo-bonds
containing the compounds designed to locally release 5-aminosalicylicacid were synthesized
bensalazine, balsalazide and olsalazine. In1986, Saffron and coworkers described the use of
azo containing acrylic polymers to the delivery of protein drugs like insulin to the colon. [1]
ANATOMY AND PHYSIOLOGY OF COLON:
Irrespective  of  therapy  desired  for  local  (colonic)  or  systemic  delivery  of  drug,  the
development and aim of the drug delivery to colon remains same[2], that is
 The drug must not absorb from other regions of the gastro intestinal tract (GIT).
 It should only suffer negligible degradation in the small intestine lumen.
 The release of the drug in the colon should be at quantitatively controlled rate and the
released drug in the colon should be absorbed from the lumen of the large intestine
without any appreciable degradation.
In order to meet these properties, a thorough knowledge of the anatomy and physiology of
GIT is required. The GI tract is divided into stomach, small intestine and large intestine. In
GIT, the large intestine extending from the ileocecal junction to the anus is divided in to three
main parts. These are the colon, the rectum and anal canal. 
The entire colon is about 5 feet (150 cm) long, and is divided in to five major segments.
Peritoneal folds called as mesentery which is supported by ascending and descending colon.
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The right colon consists of the cecum, ascending colon, hepatic flexure and the right half of
the transverse colon. The left colon contain the left half of the transverse colon, descending
colon,  splenic  flexure  and  sigmoid.  The rectum is  the  last  anatomic  segment  before  the
anus[3]. The human GIT and colon were shown in Figure1. and Figure 2. respectively.
The  colon  is  a  cylindrical  tube,
 made up  of  four-layers,  serosa,  muscularis  externa,  sub
mucosa, and mucosa. The colon does not have villi, but in the presence of plicae semilunares
(cresentic  folds)  the  intestinal  surface  of  the  colon  is  increased  to  approximately  1300
cm2.sub mucosa, and mucosa. 
The major function of the colon is creation of suitable environment for the growth of colonic
microorganisms, storage reservoir of faecal contents, expulsion of the contents of the colon at
an appropriate time and absorption of potassium and water from the lumen[4] . The absorptive
capacity is very high, in each about 2000ml of fluid enters the colon through the ileocecal
valve from which more than 90% of the fluid is absorbed. On average, it has been estimated
that the colon contains only about 220 gm of wet material equivalent to just 35 gm of dry
matter.  The majority of  this  dry matter  is  bacteria.  Properties  of  GI tract  were shown in
Table1.
Figure 1: Structure of human GIT
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                                                Figure 2: Structure of colon
           Table 1: Properties of Gastro Intestinal Tract
Region of GIT Property Measured value
Total GIT
Small intestine
-Duodenum
-Jejunum
-Ileum
Large intestine
-Cecum
-Ascending colon
-Descending colon
-Transverse colon
Surface area
Length
Length
2-106
 cm2
20-30 cm
150-250 cm
200-350 cm
6-7 cm
20 cm
45 cm
30 cm
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-Sigmoid colon
-Rectum
-Anal canal
Small intestine
Large intestine
Stomach
Duodenum
Jejunum
Ileum
Colon
Rectum
Colon
-Right
-Mid
-Left
Internal diameter
pH 
Redox potential
40 cm
12 cm
3 cm
3-4 cm
6 cm
Fasted 1.5-2.0, fed 3.0-5.0
5-7
6-7
7
5.5-7
7
- 415
- 400
- 380
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FACTORS AFFECTING COLON ABSORPTION:
1.  Physical properties of drug such as pKa and degree of ionization.
2.  Colonic residence time as commanded by GIT motility.
3.  Degradation by bacterial enzymes and metabolic products.
4.  Local physiological action of drug.
5.  Selective and non-selective binding to mucus.
6.  Disease state.
TRANSIT THROUGH GIT:
The drug delivery systems first enter into stomach and small intestine via mouth and then
reach colon. The nature and pH of gastric secretion and gastric mucus influence the drug
release and absorption. In order to reach colon in an intact form, the drug delivery systems
should surpass the barriers in the stomach and small intestine. Gastrointestinal transit varies
from 1 hr to 3 hrs depending upon the condition (fasting or non-fasting). Normally, the small
intestinal transit is not influenced by the physical state, size of the dosage form and presence
of food in the stomach. The mean transit time of the dosage form is about 3-4 hrs to reach the
ileocecal junction and the time period is consistent. During this period the dosage form is
exposed  to  enzymes  present  in  small  intestine.  Compared  to  the  other  region  of  GIT,
movement of material through the colon is slow. Total time for transit tends to be highly
variable and influenced by number of factors such as diet particularly dietary fibre content,
mobility, stress, disease condition and drugs. The colonic transit time of a capsule in adult is
20-35 hrs. Improved residence time with subsequent longer transit time and the contact of
dosage form with micro flora in colon govern the release and absorption of drug from dosage
form as shown in figure 3.
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Figure 3: Fate of CDDS tablet after administration
COLONIC MICROFLORA [5]:
The human alimentary canal is highly populated with bacteria and other microflora at both
ends,  the  oral  cavity and  the  colon/rectum.  In  between  these  two sites,  the  GIT is  very
sparsely populated with microorganisms. Microorganisms of the oral cavity do not affect oral
drug  delivery  systems  and  as  such  will  not  be  considered  here  further.  However,  gut
microflora of the colon have a number of implications in health and the treatment of disease
such as IBD. This section presents some background information on gut micro flora as it
relates  to  colonic-based  delivery  system.  Concentration  of  gut  microflora  increses
considerably in the terminal ileum to reach extraordinarily high levels in the colon . The gut
bacteria are capable of catalyzing a wide range of metabolic events.  Many colon-specific
drug delivery systems  on enzymes unique to gut micro flora to release active agents in the
colon.  However,  only  two  or  three  enzyme  systems  have  been  exploited  in  this  area:
azoreductases and glycosidases (including glucuronidase). A large number of polysaccharides
are  actively  hydrolyzed  by  gut  microflora  leading  to  the  possibility  of  using  naturally
occurring biopolymer as drug carriers. In addition, ethereal sulfate prodrugs or carboxylated
prodrugs may be metabolized in the colon to the parent drug leading to local delivery in the
colon. There is certainly room for innovative approaches to carry and release drugs in the
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colon based on the metabolic capabilities of the colon microflora. Azo-reductases produced
by colon play a central role in a number of delivery systems, most notably in catalyzing the
release of 5-ASA from a variety of prodrugs. The second class of enzymes used to trigger the
release of drugs in the colon is glycosidases (including glucuronidases). The main bacterial
groups  responsible  for  beta-glycosidases  activity  are  lactobacilli,  bacteroides  and  bifido
bacteria.  As  with  azo-reductase  activity,  the  level  of  bacterial  glycosidase  activity in  the
gastrointestinal tract is associated with the concentration of bacteria in a given region.
STOMACH AND INTESTINAL pH:
Generally, the release and absorption of orally administered drugs are influenced by the GI
pH. The gradient in the GIT is not in an increasing order. In stomach the pH is 1.5-2 and 2-6
in fasted and fed conditions respectively. The acidic pH is responsible for the degradation of
various pH sensitive drugs and enteric coating may prevent it.  In  small  intestine,  the pH
increases slightly from 6.6-7.5 and decreases to 6.4 in colon.
Radio-telemetry shows the highest pH level (7.5±0.5) in the terminal ileum. On entry into the
colon, the pH drop to 6.4+0.6.  The pH in the mid colon is 6.6+0.8 and in the left  colon
7.0+0.7.  Since there is  minimal  variation in  the  pH from ileum to colon,  apparently pH
dependent polymer drug delivery may not be much selective. However, possible exploitation
of  pH  variation  in  GIT  leads  to  successful  development  of  various  colonspecific  drug
delivery systems.
GENERAL CONSIDERATIONS FOR DESIGN OF COLONIC FORMULATIONS:
Formulations for colonic delivery are, in general, delayed release dosage forms which may be
designed either to provide a ‘burst release’ or a sustained / prolonged /targeted.
i. Pathology of disease, especially the affected parts of the lower GIT (shown in figure 4)
ii. Physicochemical and biopharmaceutical properties of the drug such as solubility, stability
and permeability at the intended site of delivery.
iii. The preferred release data of the drug.
Very common physiological  factor  which  is  considered  in  the  design  of  delayed  release
colonic formulations is pH gradient of the gastrointestinal tract. In normal healthy subjects,
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there is a progressive increase in luminal pH from the duodenum (pH is 6.6±0.4) to the end of
the ileum (pH is 7.5 ± 0.5), a decrease in the cecum (pH is 6.4 ± 0.6) and then a slow rise
from the right to the left colon with a final value of 7.0 ± 0.7. Some reports suggested that
alterations  in gastrointestinal  pH profiles may occur in patients  with inflammatory bowel
disease, which should be considered in the development of delayed release formulations [6].
Figure 4: Colonic Diseases
DRUGS SUITABLE FOR CDDS:
         The following different categories of drugs are suitable for colon drug delivery.
 Drugs used to treat  irritable bowel disease (IBD) require local delivery at  drug to
colon  e.g.  Sulfasalazine,  Olsalazine,  Mesalazine,  steroids  like  Fludrocortisone,
Budesonide, Prednisolone and Dexamethasone.
 Drugs to treat colonic cancer require local delivery e.g. 5-Fluorouracil, Doxorubicin,
and Methotrexate.
 Protein  and  peptide  drugs  -  eliminating  drug  degradation  e.g.  growth  hormones,
Calcitonin, Insulin, Interleukin, Interferon and Erythropoietin.
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 To treat the infectious diseases like (Amoebiasis & Helminthiasis) which requires site
specific delivery e.g. Metronidazole, Mebendazole and Albendazole,
 To treat  rheumatoid arthritis  (NSAIDS),  nocturnal  asthma, angina require delay in
absorption due to circadian rhythms.
 Drugs which it shows more selective absorption in colon than small intestine due to
small extent of paracellular transport e.g. Glibenclamide, Diclofencac, Theophylline,
Ibuprofen, Metoprolol, and Oxyprenolol.
LIMITATIONS AND CHALLENGES IN COLON TARGETED DRUG DELIVERY:
1. One  challenge  in  the  development  of  colon-specific  drug  delivery  systems  is  to
establish an appropriate dissolution testing method to evaluate the designed system
in-vitro. This is due to the rationale after a colon specific drug delivery system is quite
diverse.
2. As a site  for  drug delivery,  the colon offers a  near  neutral  pH,  reduced digestive
enzymatic activity,  a  long transit  time and  increased  responsiveness  to  absorption
enhancers; The targeting of drugs to the colon is very complicated. Due to its location
in the distal part of the alimentary canal, the colon is particularly difficult to access. In
addition to that the wide range of pH values and different enzymes present throughout
the gastrointestinal tract, through which the dosage form has to travel before reaching
the target site, further complicate the reliability and delivery efficiency.
3. Successful delivery through this site also requires  the drug to be in solution form
before it arrives in the colon or alternatively, it should dissolve in the luminal fluids of
the colon, but this can be a limiting factor for poorly soluble drugs as the fluid content
in the colon is much lower and it is more viscous than in the upper part of the GI tract.
4.  The stability of the drug is also a concern and must be taken into consideration while
designing the delivery system. The drug may potentially bind in a nonspecific way to
dietary residues, intestinal secretions, mucus or faecal matter.
5. The  resident  microflora  could  also  affect  colonic  performance  via  metabolic
degradation  of  the  drug.  Lower  surface  area  and  relative  ‘tightness’ of  the  tight
junctions in the colon can also restrict drug transport across the mucosa and into the
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systemic circulation 
The literature also suggested that  the cytochrome P-450 (3A) class  of drug metabolizing
enzymes have lower activity in the colonic mucosa. A longer residence time of 3 to 5 days
results in elevated plasma levels of the drugs and therefore higher bioavailability in general,
but especially for drugs that are substrates for this class of enzyme. 
ADVANTAGES:
Colon-specific drug delivery system offers the following therapeutic advantages [1] [7] 
• Reducing the adverse effects in the treatment of colonic diseases (ulcerative colitis,
colorectal cancer, crohn’s disease etc.)
• By producing the environment  for  peptides and proteins  when compared to upper
gastrointestinal tract.
• Minimizing extensive first pass metabolism of steroids.
• Preventing the gastric irritation produced by oral administration of NSAIDS.
• Delayed release of drugs to treat angina, asthma and rheumatoid arthritis.
• Drugs which are destroyed by the stomach acid and/or metabolized by pancreatic
enzymes are slightly affected in the colon. [8]  [9] 
DIFFERENT APPROACHES TO TARGET THE COLON
Different approaches to the colon were shown in Table 2.
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Table 2: Approaches for the development of colon targeted drug delivery 
Approach Basic feature
I. Chemical Approaches
1. Azo conjugates The drug is conjugated via an azo bond
2. Cyclodextrin conjugates The drug is conjugated with cyclodextrin
3. Glycosidic conjugates The drug is conjugated with glycoside
4. Glucuronide conjugate  The drug is conjugated with glucuronate
5. Dextran conjugates The drug is conjugated with dextran
6. Polypeptide conjugates The drug is conjugated with polypeptide
7. Polymeric prodrugs The drug is conjugated with polymer
II. Pharmaceutical Approaches
1. Coating with polymer
i. Coating with pH-sensitive polymer Formulation  coated  with  enteric  polymers
release  drug  when  pH  moves  towards
alkaline range
ii. Coating with biodegradable polymer Drug is released following degradation of the
polymer due to the action of colonic bacteria
2. Embedding in matrices
i. Embedding in biodegradable
polysaccharides
The  embedded  drug  in  polysaccharide
matrices  is  released  by  swelling  and
biodegradable action of polysaccharides.
ii. Embedding in pH sensitive matrices Degradation of pH sensitive polymer in the
GIT releases the embedded drug
3. Timed released systems
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4. Redox-sensitive polymers
5. Bioadhesive system Drug coated  with bioadhesive polymer  that
selectively  provides  adhesion  to  colonic
mucosa.
6. Coating of miroparticles Drug  is  released  through  semi-permeable
membrane
7. Osmotic controlled delivery Osmotic pressure
CHEMICAL OR PRODRUG APPROACH:
A prodrug is a pharmacologically inactive derivative of a parent drug molecule that requires
spontaneous enzymatic transformation in vivo to release the active drug as shown in figure-5.
In this method the prodrugs are designed to undergo minimum absorption and hydrolysis in
the upper GIT and undergo enzymatic hydrolysis in the colon, there by releasing the active
drug  moiety  from  the  carrier.  Different  types  of  conjugates  are  used  to  prepare  5-ASA
prodrugs,  which  are  succeed  in  releasing  the  5-ASA  in  colonic  region.  They  are
biodegradable poly (ether-ester) azo polymers[10] , azo-linked polymeric prodrugs[11] , acrylic
type polymeric prodrugs  and cyclo-dextrin prodrugs . Glucuronide prodrugs were developed
for cortico-steriod to deliver the drug to the large intestine of colitic rats[12].  Azo-containing A
urethane-based analogue containing an azo aromatic linkage in the backbone was synthesized
by reacting touline-2, 6- di-isocyanate with a mixture of an aromatic azodiol[13]. 
Cyclodextrin prodrugs were prepared by conjugating 5-ASA on to the hydroxyl groups of
α-,  β-,  γ-cyclodextris  through an ester  linkage and investigated the  release in  cecum and
colon.  After  oral  administration  in  rats  the  conjugate  passed  through stomach  and  small
intestine  without  degradation  or  absorption  and  in  the  cecum  and/or  colon  site-specific
degradation  of  conjugate  released  5-ASA.  An azo  prodrug  of  5-ASA with  histidine  was
synthesized for targeted drug delivery to the inflammated gut tissue in inflammatory bowel
disease. The synthesized prodrug was found to be equally effective in mitigating the colitis in
rats, as that of sulfasalazine without the ulcerogenicity of 5-ASA and adverse effective of
Sulfasalazine .
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In a recent study by Yunjin et al. (2006), explained the potential of 5- amino salicyliltaurine
as a colon specific prodrug of 5ASA by in vivo evaluation to treat experimental colitis. The
prodrug was prepared by conjugating 5ASA with taurine and tested in 2,4,6, trinitrobenzene
sulfonicacid  (TNBS)  induced  colitis  rats.  Taurine  conjugation  of  5-ASA greatly  reduced
absorption  of  5-ASA from  the  intestine.  Oral  administration  of  the  conjugate  not  only
increased  the  colonic  delivery  efficiency  of  5-  ASA but  also  decreased  the  systemic
absorption of free 5-ASA as compared to other conjugates prepared with glycine and aspartic
acid. Taurine conjugate of 5-ASA is slightly more effective than sulfasalazine in alleviating
the  colonic  inflammatory  induced  by  TNBS.  N-Nicotinoylglycyl-2-(5-  fluorouracil-1-yl)-
D,L-glycine was synthesized as a prodrug of 5-fluorouracil colon specific drug delivery. 
      Figure 5: Prodrugs used for targeted drug delivery to colon
pH- DEPENDENT SYSTEM:
The basic principle in this method is the coating of the tablets/pellets etc with various pH
sensitive  polymers  (given in  Table  3),  which will  produce delayed release and also give
protection from gastric fluids. The selected polymers to colon targeting should be able to
withstand the pH of the stomach and small intestine. Methacrylic acid esters are the most
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commonly used polymers for colon targeting because they are soluble at above pH 6. The
ideal polymer should be able to withstand the lower pH of the stomach and of the proximal
part of the small intestine but able to disintegrate at neutral or shortly alkaline pH of the
terminal ileum and preferably at ileocecal junction. Eudragit L and Eudragit S are widely
used in the colon targeting because Eudragit L is soluble at pH 6 or above and Eudragit S is
soluble at pH 7 or above and the combination of these polymers give the desirable release
rates.
A novel colon-specific drug delivery system was developed with methacrylate derivatives of
5-ASA using pH sensitive swelling and drug release properties. Composite film coated tablets
of 5-ASA were prepared for colon specific delivery. In this method 5-ASA core tablets were
prepared  and  coated  with  dispersion  containing  Eudragit  RS  and  dessterrifed  pectin,
polygalacturonic acid, or its potassium and sodium salts. Negligible drug release occurred
during first five hours where the coated tablets were in the stomach and small intestine. After
that the release of 5-ASA from coated tablets occurred linearly as a function of time due to
the action of pectinolytic enzymes [14].
A comparison study of  the usual  enteric-coated polymers viz.  Eudragit,  Cellulose acetate
phthalate with Shellac and Ethyl cellulose as carriers for colon specific drug delivery was
conducted to select a suitable carrier. In this study lactose based Indomethacin tablets were
prepared and coated with one of the above coating polymers to a varying coating thickness.
From the dissolution data at a coat concentration of 3% shellac provided the most appropriate
polymer coat  for colon-specific drug delivery.  Variation in the shellac coat  thickness  can
facilitate drug delivery to terminal ileum, distal or proximal colon [15].
EUDRACOLTM  is a novel pH and time controlled multiple unit colon drug delivery systems
in which the pellets coated with Eudragit RL /RS and Eudragit FS 30D. Caffeine is used as
marker  drug  for  pharmacokinetic  studies  using  the  multi  particle  principle  and  delayed
release in the colon; reduction of dosing frequency may be achieved. Due to its  specific
coating structure, the Eudracol system offers a new dimension for colon drug targeting via the
oral route [16]. 5-ASA pellets were coated with the enteric coating solution containing different
ratios at Eudragit L-100 and Eudragit S-100 for colon drug delivery. The release of 5-ASA is
depending on the thickness of the layer and the ratio of Eudragit copolymers[17]. pH-sensitive
hydrogels  were  prepared for  colonic delivery of  therapeutic  peptides,  proteins.  New pH-
sensitive glycopolymers were developed by free radical polymerization of methacrylic acid
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and 6-hexandiol diacrylate and 6- hexandiol propoxylate diacrylate[18].
                            Table 3: List of pH dependent polymers [19,20]
pH dependent polymers Threshold pH
Polyvinyl acetate phthalate (PVAP)
(Coateric®)
5.0
Cellulose acetate phthalate (CAP)
(Aquateric®)
6.2
Cellulose acetate trimellitate (CAT) 5.5
Hydroxypropyl methylcellulose acetate
succinate (HPMCAS)
LF Grade
MF Grade
HF Grade
≥5.5
≥6.0
≥6.8
Hydroxypropyl methylcellulose phthalate
(HPMCP)
HP-50
HP-55 and HP-55S
≥5.0
≥5.5
Shellac (MarCoat 125 & 125N) 7.0
Eudragit® FS 30D ≥7.0
Methacrylic acid copolymer, Type A
(Eudragit®L-100 and Eudragit® L12, 5)
≥6.0
Methacrylic acid copolymer, Type B
(Eudragit®S-100 and Eudragit® S12, 5)
≥7.0
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Methacrylic acid copolymer, Type C
(Eudragit® L100-55)
≥5.5
Methacrylic acid copolymer dispersion
(Eudragit® L30D)
5.6
TIME-DEPENDENT SYSTEM
The basic principle involve in the system is the release of drug from dosage form should be
after a predetermined lag time to deliver the drug at the right site of action at right time and in
the right amount  [21]. Colon targeting could be achieved by an incorporating a lag time into
formulation equivalent to the mouth to colon transit time. A nominal lag time of five hours is
usually considered sufficient to achieve colon targeting. In this method the solid dosage form
coated with different sets of polymers (listed in Table 4) and the thickness of the outer layer
determines the time required disperse in aqueous environment.
Colon drug delivery system of Diclofencac sodium was developed using a time dependent
approach. In  this,  Diclofencac sodium tablets were coated with ethyl cellulose in ethanol
solution cooling diethyl phthalate as a plasticizer and PEG 400 as channelling agent. The lag
time of Diclofenac Sodium release was primarily controlled by thickness of ethyl cellulose
coating  layer.  By  increasing  the  thickness  of  an  coating  layer,  longer  the  lag  time  of
Diclofenac sodium release . Formulation of an fast release enteric coated tablets for colon
drug delivery using two different approaches . In the first approach core tablets (celicoxib as
a  model  drug)  were  prepared  using  different  concentrations  of  super  disintegrates  like
cross-linked PVP. In second approach concentrations tablets were prepared using potassium
chloride, sodium chloride as osmogen. Then they are coated with Eudragit L-100: Eudragit S-
100 in the ratio of 1:5 to achieve a desired thickness. The tablets with super disintegrates are
fast released where the tablets with osmogen are sustain released. The coat weight determines
the lag phase that required eliminating the release in stomach and small intestine.
Hydroxy Propyl Methyl Cellulose compression coated tablets of 5-fluorouracil were studied
for colon drug delivery that based on time-dependent approach. In this, the core tablet was
prepared by wet granulation method and then coated with 50% of HPMC/lactose coat powder
by  compression-coating  method.  Drug  release  characteristics  were  evaluated  in  distilled
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water by using a Chinese pharmacopoeia rotatable basket method.
MICRO FLORA  ACTIVATED SYSTEM
The principle involved in this method is degradation of polymers coated on the drug delivery
system by microflora present in colon and there by release of drug load in colonic region
because the bio environment inside the human GIT is characterized by presence of complex
microflora, especially the colon is rich in microorganisms[22]. In this method drugs and dosage
forms are coated with the biodegradable polymers (Table 4) i.e., the polymers degrade due to
influence  of  colonic  microorganisms.  When  the  dosage  form passes  through  the  GIT,  it
remain  intact  in  the  stomach  and  small  intestine  where  very  little  microbial  degradable
activity is present which is insufficient for cleavage of the polymer coating.5-ASA pellets
was coated with amylose for colon drug delivery, in which amylose coating solution was
prepared  along  with  Ethocel  ,  Eudragit  RS/RL 30D and  Aquacoat  ECD  30[23].  Chitosan
capsules  was  developed  for  colon  specific  delivery  of  insulin  and  its  absorption  was
improved by addition of absorption enhancers (Sodium glycocholate,  Sodium oleate)  and
protease  inhibitors  like  bacitracin,  aprotinin.  Low  swelling  guar  gum  prepared  by
corsslinking  with  glutaraldehyde  that  is  used  as  a  colon-specific  drug  carrier.  Chitosan
succinate and chitosan phthalate were synthesized by reacting the chitosan separately with
succinic anhydride and phthalic anhydride. These semi synthetic polymers produced stable
matrices of Diclofencac sodium for colon specific delivery that had more resistance to acidic
condition and improved drug release profile under basic conditions [24]. 
Organic acids like succinicacid, tartaricacid and citricacid were used as excipients in matrix
granules to modify the drug release for colon-specific drug delivery.  Amylose-Ethyl cellulose
film coatings obtained from organic-based solvents were investigated as potential vehicles for
colon drug delivery. In this method amyulose-butanol dispersion and ethyl cellulose in ethyl
lactate/ethanol/propanol  with  dibutylsebacate  as  plasticizer  were  mixed  in  various
proportions  and  coated  on  5-ASA pellets  to  achieve  desired  thickness.  The drug  release
regulating parameters are thickness of coating and ratio of amylose to ethyl cellulose. The
release of drug is irrespective of the solvent used for coating. Formulation containing 1 part
amylase and 1 part  ethyl cellulose of coating thickness,  15% TWG, gives desired release
profiles of 5-ASA for colon targeting[25].
Phosphated cross-linked guar gum was prepared for colon-specific drug delivery. Guar gum
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cross-linked  with increasing amounts  of  trisodiumtrimetaphosphate  to  reduce  its  swelling
properties  for  use  as  a  vehicle  in  oral  delivery  formulations,  especially  drugs  aimed  at
localizing in the distal portions of the small bowel. Swelling of guar gum in artificial GI
fluids was reduced from 100-120- fold to 10-35-fold depending on the amount of cross linker
used [26].
Colon target  drug delivery system for  Mebendazole was developed using guar  gum as a
carrier. In this method Mebendazole matrix tablets containing various proportions of guar
gum were prepared by wet granulation technique using starch paste as a binder. From the
results 20% and 30% guar gum tablets were provided targeting of Mebendazole for local
action in the colon.  The α-cyclodextrin derivate of prednisolone-21-succinate showed anti-
inflammatory activity with low adverse effects when compared to Prednisolone alone by intra
colonical administration to rats with 2,4,6,trinitrobenzene sulfonicacid-induced colitis. The
conjugate can alleviate the systemic adverse effect  of prednisolone while maintaining the
therapeutic activity of prednisolone [27].
A chitosan-dispersed system (CDS) was developed for colon- specific drug delivery, in which
the capsule containing acetaminophen was coated with the suspension containing chitosan
powder and Eudragit RS, formed a drug release-regulating layer around the capsule. Outer
enteric coating layer prevent the dissolving of chitosan under acidic pH. The resultant enteric-
coated  CDS  capsules  reached  the  large  intestine  within  one  to  three  hours  after  oral
administration and they were degraded at the colon in beagle dogs were studied about the
lactulose as  a  carrier  for  colon-specific  drug delivery by microbial  degradation in  colon.
Enteric-coated  pectin  based  matrix  tablets  were  prepared  for  colonic  delivery  of
Theophylline.                                                                                                                           
This approach takes advantage of the combination of pH-sensitive method and microbial-
triggered system. In this method Theophylline-colon biodegradable pectin matrix tablets were
prepared and coated with enteric coating solution (Eudragit S100 in acetone) to overcome the
poor compatibility of pectin. Emdex, a hydrophilic directly compressible material was used to
prepare tablets by direct  compression. The new quaternized chitosan i.e.  triethyl  chitosan
(TEC)  is  evaluated  in  pharmaceutical  approaches  and  proved  that  there  is  a  significant
increase  in  absorption  of  poorly  absorbed  compounds  in  colon  specific  drug  delivery
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system[28].
Calcium pectinate beads was prepared for colon specific delivery of therapeutic peptides like
bovine  serum  albumin  (BSA)  by  extruding  BSA-loaded  pectin  solution  to  an  agitating
calcium chloride solution and gelled spheres were formed instantaneously by an ionotropic
gelation reaction.
The drug release was regulated by concentration of pectin, concentration of calcium chloride
and  total  drug loading. The HPMA Copolymer (N-(2-hydroxy propyl)  methacrylamide)-9
amino camptothein conjugate containing a spacer was synthesized and characterized for oral
colon specific drug delivery. The drug delivery system has potential in the treatment of colon
cancer  [29].  Zinc pectinate beads formed the strongest  network matrix in comparison with
calcium pectinate and suggested the zinc pectinate beads as efficient carriers for specific drug
delivery to colon [30].
Metronidazole tablets were prepared using various polysaccharides like guar gum, xanthan
gum,  pectin,  carrageenan,  β-cyclodextrin  for  colon  specific  drug  delivery  to  treat
ameobiasis[31]. 5-Fluorouracil compression coated tablets were prepared for colonic release of
drug using xanthan gum, boswellia gum and HPMC as the coating materials [32]. CDDS of 5-
fluorouracil was developed using pectin-ethyl cellulose as a film coat with FBC [33].
Table 4: Materials used in formulation of CDDS
Prodrug conjugates pH-Sensitive
Polymers
Materials used In
Time-Dependent
System
Microbial
degradable
polymers
Azo bond conjugates
Amino acid
(Polypeptide)
Eudragit L-100
Eudragit S-100
Hydroxy Propyl
Methyl Cellulose
Hydroxy Ethyl
Chitosan
Pectins
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conjugates
Glycoside conjugates
Glucuronide
conjugates and
Sulphate conjugates
Polymeric conjugates
Cyclodextrin
conjugates
Dextran conjugates
Eudragit L-30 D
Eudragit L-100-55
Eudragit F S 30 D
Poly Vinyl Acetate
Phthalate
Hydroxy Propyl
Methyl Cellulose
Phthalate 50
Hydroxy Propyl
Methyl Cellulose
Phthalate 55
Hydroxy Propyl Ethyl
Cellulose Phthalate
Cellulose Acetate
Phthalate
Cellulose Acetate
Trimellate
Cellulose
Ethyl Cellulose
Microcrystalline
Cellulose
Hydroxy Propyl
Methyl Cellulose
Acetate Succinate
Lactose/Behinic acid
Guar gum
Dextrans
Inulin
Lactulose
Amylose
Cyclodextrins
Alginates
Locust bean gum
Chondroitin sulphate
Boswellia gum
COMBINATION OF DIFFERENT APPROACHES OF CDDS :
An oral  colonic drug delivery system of  5-ASA has  developed using combination of  pH
dependent,  time-based  and  enzyme degradable  approaches.  The  pellets  were  coated  with
three functional layers i.e. the outer Eudragit L- 30D-55 layer for protection against GI fluids,
the intermediate layer of ethyl cellulose to inhibit the drug release during passage through the
small intestine and the inner layer of pectin for swelling and enzyme-degradation. In vitro
release studies indicate that the coated pellets completely protected the drug release in 0.1M
Hcl while the drug release was delayed for three to four hours in pH 6.8 phosphate buffer.
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Pulsatile device was formulated to achieve a time or site-specific release of Theophylline
based on chrono pharmaceutical consideration. The basic design consists of an insoluble hard
gelation capsule body filled with Eudragit microcapsules of Theophylline and sealed with a
hydrogel plug and finally the enteric device was enteric coated. In this approach, pH sensitive
and time dependent delivery systems were combined. In this the thickness of enteric coat is a
measure of protection from stomach and intestine pH. Different hydrogel polymers were used
as plugs to maintain a suitable lag period.The hydrophilic polymer content is a measure of
delayed release of theophylline from microcapsules [34].
Pectin based CDDS of 5-fluorouracil was developed using calcium pectinate gel. Calcium
pectinate gel beads were prepared by ionotropic gelation method followed by enteric coating
with Eudragit S-100 and evaluated using USP paddle type dissolution apparatus in different
simulated mediums [35].
A new microbial-triggered  colon  targeted  osmotic  pump (MTCT-OP)  was  developed  for
CDDS  based  on  chitosan  for  a  model  drug,  Budesonide.  The  combination  of  osmotic
technology and microbial-triggered mechanism had a high potential to deliver to drug load in
colonic region. In  this method the core tablet  of Budesonide was prepared with chitosan,
which is used to produce osmotic pressure, and to form the insitu delivery pores for colon-
specific drug release. Cellulose acetate in acetone along with chitosan (as pore forming agent)
was coated on tablet as a semipermeable membrane and finally coated with Eudragit L-100-
55 in ethanol as an enteric coating layer that could prevent cellulose acetate membrane from
forming pore or rupture before reaching colon region. Budesonide release from developed
system was inversely proportional to the osmotic pressure to the release medium[36]. 
HYDROGEL BASED CDDS:
Amylated pectin hydrogel beads prepared for colon specific delivery of Indomethacin and
Sulfamethoxazole[37]. Glutaraldehyde cross-linked dextran capsules were prepared for colon
targeting. Along with magnesium chloride and PEG 400 in water the capsule caps and bodies
were prepared on nylon molding pins. Then the dextran capsules were filled with model drug
(Hydrocortisone)  and drug release was studied. The drug release pattern was suitable for
colon specific  delivery  [38].  The hydrogels formed by cross-linked polyvinyl  alcohol were
suitable  for  colon  specific  drug  delivery  systems.  In  this  method  polyvinyl  alcohol  of
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different molecular weights was corss-linked with succinyl, adipoyl, or sebacoyl chloride to
obtain  hydrogel-forming  polymers.  The  hydrophilic  drugs  like  Diclofencac  sodium,
propranolol  hydrochloride  and  vitamin  B6  hydrochloride  were  used  as  model  drugs[39].
Methacrylated inulin hydrogels designed for colon targeting the proteins like Bovine serum
albumin  or  Lysozyme.  Organic  redox-initiated  polymerization  technique  was  used  to
fabricate pH responsive hydrogels for colon specific delivery [40].
Glutaraldehyde corss-linked guar gum hydrogel discs were prepared as vehicles for colon
specific drug delivery of ibuprofen. Percent of drug release increased with glutaraldehyde
concentration. Cross-linking decreased the swelling of guar gum. The fabricated hydrogels
discs may prove to be beneficial as colon-specific drug delivery vehicles for poorly water-
soluble drugs like ibuprofen [41].
Novel complex hydrogel beads were prepared using pectin and zein for colon-specific drug
delivery. Pectin/Zein complex hydrogel beads showed the capability to protect incorporated
drugs from premature release into stomach and small  intestine.  The inclusion of  a small
portion of  zein (a  protein from corn) in  to  the pectin efficiently suppressed the swelling
behavior of pectin, thus stabilizing the structural property of the pectin networks. Likewise
the pectin networks protected the bound zein from protease digestion. These properties made
pectin/zein complex beads a promising system for colon specific drug delivery  [42]. Cross-
linked HPMC hydrogels were synthesized and used to develop 5-ASA colon drug delivery
system [43].
NOVEL DRUG DELIVERY SYSTEMS FOR CDDS:
Now a days the basic CDDS approaches are applied to formulate novel drug delivery systems
like Multi particulate systems, Microspheres, Liposomes, Microencapsulated particles etc. 
Multi particulate systems
Multiparticulates (pellets, non-peariles etc.) are used as drug carriers in pH-sensitive, time-
dependent and microbially control systems for colon targeting. Multi particulate systems have
several  advantages  in  comparison  to  the  conventional  single  unit  for  controlled  release
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technology, such asmore predictable gastric emptying and fewer localized adverse effect than
those of single unit tablets or capsules.
A multi particulate dosage form was prepared to deliver active molecules to colonic region,
which  combines  pH  dependent  and  controlled  drug  release  properties.  This  system  was
constituted by drug loaded  cellulose  acetate  butyrate  (CAB).  Microspheres  loaded  by an
enteric polymer (Eudragit S). Here the enteric coating layer prevents the drug release below
pH 7. After that CAB microspheres efficiently. controlled the release of  Budesonide, which
is depended on the polymer concentration in the preparation . Azo polymer coated pellets
were  used  for  colon-specific  drug  delivery to  enhance  the  absorption  of  insulin  and  Eel
Calcitonin.  A multi particulate chitosan dispersed system (CDS) was prepared for colon drug
delivery and it was composed of the drug reservoir and the drug release-regulating layer,
which was composed of water insoluble polymer and chitosan powder. The drug reservoir
was prepared by drug containing multiparticulates like Non-peariles in the study. In this study
the multi particulate CDS was adopted not only for colon specific drug delivery but also for
sustained drug delivery.
A multi particulate system combining pH sensitive property and specific biodegradability was
prepared  for  colon  targeted  delivery of  Metronidazole.  The multi  particulate  system was
prepared by coating cross-linked chitosan microspheres explorting Eudragit L-100 and S-100
as pH sensitive polymers. The in-vitro drug release studies shows that no release of drug at
acidic pH and higher drug release was found in presence of rat caecal contents indicating
susceptibility of chitosan matrix to colonic enzymes released from rat caecal contents. High-
Amylose  cornstarch  and  Pectin  blend  micro-particles  of  Diclofencac  sodium  for  colon-
targeted delivery were prepared by spray drying technique. The blending of high-amylose
cornstarch  with  pectin  improved  the  encapsulation  efficiency  and  decreased  the  drug
dissolution in the gastric condition from pectin based micro-particles. The drug released in
colonic region by the action of pectinase from micro-particles  [44]. Investigated the effect of
sodium glycocholate as an absorption promoter on orally administrated insulin absorption
utilizing a colon-targeted delivery system. A novel insulin  colon-targeted delivery system
(Insulin- CODES) contains insulin, lactulose as a trigger for colon-specific release, citricacid
as a solubilizer of insulin, meglumine as a pH adjusting agent and sodium glycocholate as an
absorption promoter.
Microspheres of anti-cancer drugs:
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Cross-linked  guar  gum  microspheres  containing  Methotrexate  were  prepared  and
characterized for local release of drug in the colon for efficient treatment of colorectal cancer.
In this method glutaraldehyde was used as a cross-linking agent and guar gum microspheres
were prepared by emulsification method. From the results of in vitro and in vivo studies the
Methotrexate loaded cross linked guar gum microspheres delivered most of the drug load
(79%) to the colon, where as plain drug suspensions could deliver only 23% of three total
dose to the target tissue [45]. Colon specific microspheres of 5-fluorouracil were prepared and
evaluated for the treatment of colon cancer.  In  this method core microspheres of alginate
were prepared by modified emulsification method in liquid paraffin and by cross-linking with
calcium chloride.  The core microspheres were coated with Eudragit S-100 by the solvent
evaporation technique to prevent drug release in the stomach and small intestine. The results
showed  that  this  method  had  great  potential  in  delivery  of  5-fluorouracil  to  the  colon
region[46].
Advantages of microspheres:
1.  Provide selective passive targeting to tumour tissues.
2.  Flexibility to couple with site-specific ligands to achieve active targeting.
3.  Increased efficacy and therapeutic index.
4.  Increased stability via encapsulation.
5.  Reduction in toxicity of the encapsulated agent.
6.  Improved pharmacokinetic effects.
EVALUATION OF CDDS:
The drug release in the colonic region from different CDDS is evaluated by different
methods of  in vitro and  in vivo release studies,  which show the success rate  of different
designs of colon drug delivery systems. Depending upon the method of preparation different
evaluation methods are proposed. A successful colon specific drug delivery system is one of
that  remains  intact  in  the  physiological  environment  of  stomach and small  intestine,  but
releases the drug in the colon.
In-vitro Evaluation:
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Different in vitro methods are used to evaluate the colonic drug delivery systems. In
in-vitro studies  the  ability  of  the  coats/carriers  to  remain  intact  in  the  physiological
environment of the stomach & small intestine is assessed by drug release studies in 0.1N Hcl
for two hours (mean gastric emptying time) and in pH 7.4 phosphate buffer for three hours
(mean small intestine transit time) using USP dissolution apparatus. In case of micro flora
activated system dosage form, the release rate of drug is tested in vitro by incubating in a
buffer medium in the presence of either enzymes (e.g. pectinase, dextranase) or rat/guinea pig
rabbit  caecal  contents.  The amount of drug released at  different  time intervals during the
incubation is estimated to find out the degradation of the carrier under study [47].
In-vivo Evaluation:
The successful development of the CDDS is ultimately determined by its ability to
achieve release in colonic region thus exerts the intended therapeutic effect. When the system
design  is  concerned  &  prototype  formulation  with  acceptable  in-vitro characteristics  is
obtained, in vivo studies are usually conducted to evaluate the site specificity of drug release
and to obtain relevant pharmacokinetic information of the delivery system. Although animal
models have obvious advantages in assessing colon specific drug delivery systems, human
subjects  are  increasingly  utilized  for  evaluation  of  this  type  of  delivery  systems.  The
preferable animals to evaluate CDDS are rats, guinea pigs and dogs.[48] γ-scintgraphic studies
were  conducted  in  human  volunteers  with  technetium-99m-DTPA as  tracers  in  sodium
chloride core tablets compression coated with guar gum showed that the gum coat protect the
drug  (tracer)  from  being  released  in  the  stomach  and  small  intestine.  On  entering  the
ascending colon, the tablets commenced to release the tracer indicating the breakdown of
gum coat by the enzymatic action of colonic bacteria.[49] Technetium-99m-DTPA was used as
a tracer for γ- scintigraphy evaluation of colon specific guar gum directly compressed matrix
tablets in human volunteers.[50] The scintigraphic evaluation conducted for capsule type colon
specific drug delivery system in human healthy volunteers.[51]  In a study by Krishnaiah et al.
(2001),[54] showed the effect of Metronidazole and Tinidazole (antimicrobial agents) on the
release  of  Albendazole  from  guar  gum  based  colon  specific  matrix  tablets.  The  active
antimicrobial  agents  (7  days)  treatment  of  rat  caecal  content  decreased  the  release  of
Albendazole due to decreased levels of anaerobic bacteria present in rat.
                    Table 5: Marketed colon specific drug delivery systems
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Drug Trade Name Coating Polymers
Mesalazine Claversa
Asacolitin
Mesazal
Asacol
Eudragit L 100
Eudragit S
Eudragit L 100
Eudragit S
Budesonide Entrocort
Budenofalk
Targit
Eudragit L100-55
Eudragit S
Coated Starch Capsule
Sulfasalazine Azulfidine
Colo-Pleon
Cellulose acetate phthalate
Eudragit L100-55
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REVIEW OF LITERATURE
• HN Shivakumar et al., (2006) [52]  prepared the system comprising of Eudragit S-100
coated  pellets  was  designed  for  chronotherapeutic  delivery  of  Diltiazem
hydrochloride.  The drug  loaded  core  pellets  were  produced  by aqueous  extrusion
spheronization technique using microcrystalline cellulose as a spheronizing aid and
PVP K 30 as a binder. Different coat weights of Eudragit S-100 were applied to the
drug  loaded  pellets  in  an  automatic  coating machine  to  produce  the  pH sensitive
coated pellets.  Pellets performed following pH progression method showed that the
drug release from the coated pellets depended on the coat weights applied and pH of
the dissolution media.
• Nagpal et al., (2006) [53]  synthesized a prodrug of 5-ASA with histidine for targeted
drug  delivery  to  the  inflammated  gut  tissue  in  inflammatory  bowel  disease.  The
synthesized prodrug was found to be equally effective in mitigating the colitis in rats,
as that of Sulfasalazine without the ulcerogenecity of 5-ASA and adverse effects of
Sulfasalazine.
• Prabal Kumar et al.,  (2007) [54]  prepared Megaloporous controlled release tablets of
Diclofenac sodium (DS) were prepared with two kinds of granules. One of them is the
restraining-phase matrix granule (RMG) and it controls the release rate of the drug.
The other one is the soluble housing-phase matrix granule (HMG) and controls liquid
penetration into the system. Carnauba wax and Eudragit L 100 polymers were used to
constitute the restraining and housing matrix phases, respectively. In vitro drug release
study was carried  out in  simulated gastric  fluid (pH 1.2)  for  the first  2  h  and in
phosphate buffer (pH 7.2) for the next 10 h following USP 25 paddle method. The
fabricated  megaloporous  matrix  tablets  released  only  3  to  5%  of  DS  in  pH  1.2
depending on the proportion of carnauba wax used in the RMG.
• Parasuram Rajam Radhika et al., (2008) [55]   formulated colon specific aceclofenac
microspheres  as  Aceclofenac  delayed  release  microspheres  employing  cellulose
acetate  phthalate  as  enteric  polymer.  The  effect  of  various  other  modern  enteric
polymers HPMCP, Eudragit S 100 and L 100 on the release of aceclofenac from the
CAP microspheres has been evaluated. The studies revealed that Eudagit polymers
exhibited negative effect on the release of CAP microspheres.
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• Naikwade  Sonali  R  et  al.,  (2008) [56] formulated  matrix  tablets  of  Tinidazole
employing swellable polymers (HPMC K4M & K15M) and Eudragit (S-100 & L-
100)  which  were  then  enteric  coated  to  provide  localised  action  in  colon.
Bioavailability study showed that greater portion of Tinidazole was released in Large
intestine and drug level in plasma was above 4 µg/mL in blood for 24 hrs
 
• Amal H. El-Kamela et al., (2008) [57]  prepared oral colon targeted delivery systems
for  treatment  of  inflammatory  bowel  disease:  Synthesis,  in  vitro and  in  vivo
assessment  and  investigated  the  potential  of  prodrugs  of  some non-steroidal  anti-
inflammatory drugs (NSAIDS) as colon targeted delivery systems for treatment of
inflammatory bowel diseases. Naproxen, Sulindac and Flurbiprofen (Fbp) were used.
•  Mohanad Naji Sahib et al., (2009) [58]   formulated Prednisolone as an oral modified
release  tablet  for  colonic  targeting.  Many  trials  were  performed  to  prepare  a
satisfactory formula  using the  wet  granulation method with  various  additives  and
coatings. The formula containing 1% Eudragit RS PM was the best with regard to
100% release of drug in comparison with other concentrations and other retardant
types. Eudragit S 100 provided the best release of drug in pH 7.4 phosphate buffer.
• Patel S.N et al., (2009) [59]  developed  colon specific drug delivery of  Prednisolone
sustained release matrix tablets for ulcerative colitis using HPMC K-4M and HPMC
K-100M as a semi synthetic polymer. Prednisolone based tablets were coated using
methacrylic acid copolymers Eudragit® S100 by spraying organic system. The matrix
tablets of Prednisolone are subjected to an in vitro drug release study using simulated
colonic fluid of pH 7.2 as the dissolution medium. The results also demonstrated that
a Eudragit® S100 can be successfully used for organic system to coat  tablets for
colon targeted delivery of drug.
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• Sateesh Kumar Vemula et al., (2010) [60]  describes on different approaches to design
and  evaluation  of  colon  specific  drug  delivery systems.  Different  approaches  are
designed based on prodrug formulation, pH sensitivity, time-dependency (lag time),
microbial  degradation  and  osmotic  pressure  etc  to  formulate  the  different  dosage
forms  like  tablets,  capsules,  multiparticulates,  microspheres,  liposomes  for  colon
targeting. The efficiency of drug delivery system is evaluated using different in vitro
and  in  vivo release  studies.  This  review  updated  that  the  research  on  different
approaches for formulation and evaluation of colon-specific drug delivery systems
(CDDS). In 1942, Svartz discovered that Sulfasalazine; the sulphanilamide prodrug of
5-aminosalicylic acid (5-ASA) is effective in the treatment of rheumatoid arthritis and
anti-inflammatory disease. The exact mode by which the drug target itself to the colon
was elucidated much later in 1970 i.e., colon specific azoreductase splits Sulfasalazine
causing the release of the active moiety 5-amino salicylic acid. After the several other
azo-bonds containing compounds designed to  locally release 5-aminosalicylic  acid
were synthesized Bensalazine, Balsalazide, Olsalazine.
• R.  Thiruganesh  et  al.,  (2010) [61]  formulated   Colon  specific  release  systems  of
Aceclofenac  by  loading  Aceclofenac  into  pectin  pellets  followed  by  coating  the
loaded pellets with pH dependent polymeric coating solution containing Eudragit L
100 and S 100 (1:4).  Pellets containing four proportions of pectin were prepared.
Eudragit  coated  pectin  pellets  prevented  release  of  the  Aceclofenac  in  the
physiological  environment  of  stomach  and  small  intestine  depending  on  the
proportion of pectin used in the formulation. 
• MS Khan et al., (2010) [62]   developed and evaluated multiparticulates of alginate and
chitosan hydrogel beads exploiting pH sensitive property for colon-targeted delivery
of theophylline.  Alginate and chitosan beads were prepared by ionotropic gelation
method followed by enteric  coating with Eudragit  S100.  The studies  showed that
formulated alginate and chitosan beads can be used effectively for the delivery of drug
to colon and a coat weight of 20% weight gain was sufficient to impart an excellent
gastro resistant property to the beads for effective release of drug at higher pH values.
• M. N. Patro et al., (2010) [63]  developed  pH - sensitive polymers Eudragit S 100 and
L 100 to prepare microspheres of 5-Fluorouracil by a simple oil /water emulsification
process. In further attempts mixtures with Eudragit S100 and L100 were prepared to
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prolong drug release. Eudragit S100, pure or in mixture,  was found to retain drug
release at pH 4.5 lower than 41% within 6 hrs. At pH 7.4, nearly immediate release
(within 30 min) was observed for pure S100, while mixtures enabled to prolong the
release slightly.
• Gaurav Tiwari et al., (2010) [64]    prepared Primary and novel approaches for colon
targeted  drug  delivery which  includes  prodrugs,  pH and  time  dependent  systems,
microbially triggered drug delivery system and their limitations.  Newly developed
CDDS,  which  includes  pressure  controlled  colonic  delivery  capsules  (PCDCS),
CODESTM and osmotic controlled drug delivery are unique in terms of achieving in
vivo site specificity and feasibility of manufacturing process. This review also focuses
on evaluations of CDDS in general.
• S.  Jose  et  al.,  (2010) [65]  developed  chitosan  microspheres  of  Ondansetron  by
emulsion cross linking method for colon targeted delivery intended to treat irritable
bowel syndrome combining pH dependent solubility by Eudragit S100 and microbial
degradability  of  chitosan  polymers.  The  optimized  formulation  was  subjected  to
microencapsulation  using  Eudragit  S100  by  solvent  evaporation  technique.
Formulation containing 1:10 core/coat ratio released lesser amount of drug in upper
GIT.
• Kulkarni  p  keshavaro  et  al.,  (2011) [66] formulated  colon  specific  Indomethacin
microspheres  as  Indomethacin  delayed  release  microspheres.  Using  pH  sensitive
polymers Eudragit S 100 and L 100. In vitro drug release study was carried out in pH
6.8 for 12 hours the percentage of drug release was found to be 95.58%. Concluded
that the Indomethacin microspheres can be successfully designed to develop sustained
drug delivery.
• Jitender mor et al., (2011) [67]  developed  for colon targeted delivery systems, The
colon route can be employed both local and systemic delivery of drugs. Treatment can
be  made  effective  if  the  drugs  can  be  targeted  directly  into  the  colon.  He  has
mentioned that the average ph of colon at various regions are ascending colon 6.4 and
transverse colon 6.0-7.4 and descending colon 6.0-7.4 pH and transit time of dosage
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form in GIT (hrs) in stomach <1(fasting),>3(fed) and in small intestine 3-4 ,in large
intestine (20-30). 
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AIM & OBJECTIVE
Aim:
The aim of this research is to design and evaluate novel Colon Specific Release Systems of
Aceclofenac  using  pH  dependent  polymer  .When  Aceclofenac  is  administered  as  the
conventional formulation, it causes gastro intestinal complications including irritation, ulcer,
bleeding and perforation. Site-specific delivery of drugs to the site of action has the potential
to  reduce  side  effects  and  to  increase  pharmacological  response.  Incorporation  of  pH
dependent  polymer  in  the  core  tablet,  minimizes  all  these  complications  which  makes  it
suitable candidate for administration by oral route. 
Objective:
 To develop pH dependent aceclofenac tablets with a view of minimizing the drug release
in the physiological environment of stomach and small intestine and to ensure maximum
drug  release  in  the  physiological  environment  of  colon  with  an  improved  patient
compliance. Incorporating Eudragit S 100 as a pH dependent polymer in the core tablet.
 Aceclofenac is used for treating ulcerative colitis , rheumatoid arthritis & osteoarthritis,
which had apparent circadian rhythms and peak symptoms in the early morning. 
 When Aceclofenac is administered orally as a conventional formulation, it is difficult to
achieve  the  desired  clinical  effect,  because  it  elicits  patient’s  non-compliance  of
administration in the early morning to co-ordinate the rhythm of rheumatoid arthritis &
osteoarthritis, due to rapid absorption of conventional formulation. 
 Aceclofenac is also used in the treatment of inflammatory bowel disease. Aceclofenac, a
non-steroidal anti-inflammatory drug exhibits better tolerance than Aspirin, Indomethacin
and Naproxen.
 To study release profile of colon specific dosage form for 12 hrs.
 To perform the stability studies for the prepared formulation.
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PLAN OF WORK
The present research work is planned according to the following steps:
1. Preformulation studies
2. Drug – Excipient Compatibility Studies by DSC and FT-IR. 
3. Preparation of  granules  of  Aceclofenac  by Wet  Granulation  using Eudragit  S-100
dissolved in isopropyl alcohol as binder and by increasing Eudragit S-100 in linear
fashion, followed by lubrication.
4. Pre-compression testing of  the prepared granules  for  bulk density,  tapped density,
compressibility index, angle of repose and Hausner’s ratio followed by compression
of the tablets.
5. Evaluation of the prepared tablets includes   
a) Physical parameters like hardness, friability, weight variation and drug content .
b) In-vitro dissolution studies
6. Optimization of  the tablet  by determining the trial  that  shows satisfactory release
profile in in-vitro release tests.
7.  Stability studies as per the ICH guidelines for a period of 30 days.
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DRUG PROFILE
ACECLOFENAC :
Aceclofenac is an orally administered phenylacetic acid derivative with effects on a variety of
inflammatory  mediators.  It  is  from  the  class  of  non-steroidal  anti-inflammatory  drug
(NSAID), related to Diclofenac.
Chemical IUPAC Name: 2-[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxyacetic acid
Chemical Formula: C16H13Cl12NO4
Chemical Structure: 
 Molecular Weight: 354.18
State: Solid
Melting Point: ⁰149 - 153 c
Solubility: Practically insoluble in water, freely soluble in acetone, soluble in alcohol.
Hydrophobicity: 3.03
Drug category: Analgesic agent, Anti-inflammatory agent
Indication: Acute pain in, Osteoarthritis, Rheumatoid arthritis, ulcerative colitis, Low back
pain, Dental Pain, Fracture and painful Pharyngitis & Tonsillitis.
Pharmacology:  Aceclofenac is  a  new phenylacetic  acid derivative provided with marked
anti-inflammatory, anti-arthritic, analgesic and antipyretic activities in animal experimental
models. While maintaining its potency, Aceclofenac demonstrates better gastric tolerance and
consequently  offers  greater  potential  security  than  other  highly  active  agents  such  as
Indomethacin and Diclofenac.
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PHARMACOKINETICS:
Absorption:
After oral administration, Aceclofenac is rapidly absorbed and the bioavailability is almost
100%.  Peak  plasma  concentrations  are  reached  approximately 1.25  to  3  hours  following
ingestion.  T  max  is  delayed  with  food  intake  whereas  the  degree  of  absorption  is  not
influenced.
Serum Protein Binding: 99.70%
Biotransformation:  Aceclofenac  is  probably  metabolized  via  CYP2C9  to  the  main
metabolite 4-hydroxyaceclofenac.
Site of Metabolism: Liver
Tmax: 1.25 to 3 hours
Cmax:  Chronic  heavy  alcohol  abusers  may  be  at  risk  of  liver  toxicity  from  excessive
aceclofenac use.  Renal impairment patients with mild renal function should be monitored
regularly since the use of NSAIDs may result in deterioration of renal function.
Half Life: 4 to 4.3 hours
Dose: 100 mg once a day
Food Interactions:  Tmax is delayed with food intake where as degree of absorption is not
influenced.
Bioavailability: 100%
Excretion:  Approximately  two-third  of  the  administered  dose  is  excreted  via  the  urine,
mainly  as  conjugated  hydroxy metabolites.  Only  1%  of  an  oral  single  dose  is  excreted
unchanged. A slower rate of elimination of Aceclofenac has been detected in patients with
decreased liver function after a single dose of Aceclofenac. In a multiple dose study using
100 mg once  daily,  there  was  no  difference  in  the  pharmacokinetic  parameters  between
subjects with mild to moderate liver cirrhosis and normal subjects. In patients with mild to
moderate renal impairment, no clinically significant differences in the pharmacokinetics were
observed after a single dose.
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Pharmacodynamics:
Aceclofenac is a novel NSAID known to exhibit multifactor mechanism of
action.  Aceclofenac  was  developed  in  order  to  provide  a  highly effective  pain  relieving
therapy with a reduced side effect profile.
1. Aceclofenac directly blocks PGE 2 secretion at the site of inflammation by inhibiting
IL-Beta & TNF in the inflammatory cells (Intracellular Action). Aceclofenac has been
demonstrated to inhibit cyclooxygenase (COX) activity and to suppress the PGE-2
production by inflammatory cells, which are likely to be a primary source of PGE-2.
Inflammatory cells  release IL-1 and  TNF,  which produce PGE 2 by induction of
COX-2. Aceclofenac and 4’-hydroxyaceclofenac penetrate the inflammatory cells like
polymorphonuclears, monocytes and rheumatoid synovial cells and get hydrolyzed to
the active  metabolites Diclofenac and 4’-hydroxydiclofenac which inhibit IL-1 and
TNF released by the inflammatory cells and therefore suppress production of PGE 2
at the site of inflammation.
2. Aceclofenac  stimulates  the  synthesis  of  the  extracellular  matrix  of  the  Human
Articular  Cartilages.  Aceclofenac  blocks  degeneration  and  stimulates  synthesis  of
extracellular  matrix  of  cartilages  by  inhibiting  the  action  of  different  cytokines.
Aceclofenac and the metabolites inhibit IL-6 production by human chondrocytes. This
leads to inhibition of increase of inflammatory cells in synovial tissue, inhibition of
IL-1  amplification,  inhibition  of  increased  MMP  synthesis  and  thus  ensuring
proteoglycan  production.  Aceclofenac  also  inhibits  IL-1  and  TNF  production  by
human  chondrocytes,  inflammatory  cells  and  synovial  cells  and  therefore  blocks
suppression of GAG and collagen synthesis and stimulates growth factor mediated
synthesis of GAG and collagen. 4’-hydroxyaceclofenac, a metabolite of aceclofenac
inhibits pro MMP1 and pro MMP3 produced by synovial cells (Rheumatoid Synovial
Cells) in serum and in synovial fluid and thus inhibits progressive joint destruction by
MMPs.
3. Aceclofenac inhibits Neutrophil adhesion & accumulation at the inflammatory site in
the early phase and thus blocks the pro-inflammatory actions of Neutrophils.
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EXCIPIENTS PROFILE
1. Microcrystalline Cellulose (Diluent)
2. Eudragit S100 (pH dependent Polymer)
3. Magnesium Stearate (Lubricant)
4. Talc (Glidant)
MICROCRYSTALLINE CELLULOSE [68] 
Synonyms:  Avicel, Cellulose gel, Crystalline cellulose, E460, Emocel; Fibrocel; Vivacel.
Non-proprietary Name:
BP :- Microcrystalline cellulose. 
Chemical Name: Cellulose
Emperical Formula: (C6H10O5)
Structure:
Molecular Weight: ≈36000
Functional Category:
 Absorbent, Suspending agent
 Tablet and Capsule- Diluent
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Description: White-colored, tasteless crystalline powder composed of porous particles.
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble in 
water, dilute acids and most organic solvents.
Application in pharmaceutical formulation or technology:
Microcrystalline cellulose is widely used in pharmaceuticals primarily as a diluents in oral 
tablets and capsule formulations where it is used in both wet granulation and direct 
compression processes. Microcrystalline cellulose also has some lubricant and disintegrant 
properties that make it useful in tableting and also used in cosmetics and food products.
Stability: It is a stable, though it is hygroscopic material.
Storage conditions: The bulk material should be stored in a well-closed container in a cool, 
dry place.
Incompatibilities: Incompatible with strong oxidizing agents.
EUDRAGIT [69,70]
Structure :
R1 = CH3; H
R2 = CH3
R3 = COOH; Eudragit L & S
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R4 = CH2CH2N+(CH3)Cl; Eudragit RL & RS
Advantages for coating:
 pH-dependent drug release
 Protection of actives sensitive to gastric fluid
 Protection of gastric mucosa from aggressive actives
 Increase in  drug effectiveness
 Good storage stability
 GI and colon targeting
Table 6: Threshold pH of Eudragit polymers:
Polymer Threshold pH 
Eudragit® L100
Eudragit® S100
Eudragit® L30D
Eudragit® FS 30D
Eudragit® L100-55
6.0
7.0
5.6
6.8
5.5
MAGNESIUM STEARATE [71] 
Synonyms :  HyQual, Magnesium octadecanoate, Stearic acid magnesium salt.
Chemical Name : Octadecanoic acid magnesium Salt
Emperical Formula : C36H70MgO4
Molecular Weight : 591.27
Functional category : Lubricant
Applications : It is used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25-5.0%.
Description : It is a fine, white, precipitated or milled, impalpable powder of low bulk 
density, having a faint characteristic odour and taste. The powder is greasy to touch and 
readily adheres to the skin.
Solubility : Practically insoluble in ethanol, ethanol (95%), ether and water, slightly soluble 
in benzene and warm ethanol (95%).
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Stability : Magnesium stearate is stable.
Storage conditions : It should be stored in a well-closed container in a cool, dry place.
Incompatibilities : Incompatible with strong acids, alkalis, iron salts and with strong 
oxidizing materials.
Safety : It is generally regarded as being non-toxic following oral administration. However, 
oral consumption of  large quantities may result in some laxative effect or mucosal irritation.
TALC [71]  
Synonyms : Magsil Osmanthus, Magsil Star, Purtalc, Steatite.
Emperical formula : Mg(Si2O5)4(OH)4
Functional category :
 Glidant
 In Tablet and capsule lubricant
  Anti-cacking agent
Applications : It is used as a lubricant in solid dosage forms (1-10%) and in topical 
preparations as dusting powder (90-99%).
Description : It is a very fine, white to greyish-white colored, odourless, impalpable, 
unctuous powder. It adheres to the skin, is soft to touch, and free from grittiness.
Solubility : Practically insoluble in dilute acids and alkalies, organic solvents and water.
Stability : Talc is a stable material.
Storage conditions : It should be stored in a well-closed container in a cool, dry place.
Incompatibilities : Incompatible with quaternary ammonium compounds.
Safety : Following oral ingestion talc is not absorbed systemically and may thus be regarded 
as an essentially nontoxic material.
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MATERIALS
Table No 7: Materials used:
S.NO MATERIALS USED
1 Aceclofenac Aurobindo pharma Ltd,
Hyderabad
2 Microcrystalline Cellulose Accent Microcel Industries
3 Eudragit S100 Corel Pharma Chem
4 Croscarmellose sodium FMC BioPolymer
5 Magnesium stearate Peter greven
6 Purified Talc Luzonac pharma
7 Iso Propyl Alcohol Ranchem
8 Hydrochloric acid SD fine chemical limited
9 Potassium dihydrogen orthophosphate SD fine chemical limited
INSTRUMENTS USED:
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Table no 8: Instruments used :
S.No           Instruments  Used                             Maker
1 Digital balance Sartorius  Cp  323S
2 Drier Retsch,  TG  -  100
3 Kalaweka blender Cadmach machinery  co.  pvt.  Ltd,  HD-410
AC,  Ahmadabad
4 RMG granulator Gansons  high  speed   mixer   granulator,
HSMG2
5 Differential scanning calorimetry Perkin Elmer Thermal Analyzer 
6 Tablet compressor Cadmach   machinery  co.  pvt.  Ltd,
Ahmadabad
7 Hardness tester Varian,  VK 200
8 Digimatic vernier callipers Mitutoyo  corporation,  CD – 6’’C
9 Friabilator Electro lab  EF-2, friabilator(USP), Mumbai
10 Tap density apparatus, USP Electrolab,  ETD – 1020,  Mumbai
11 FT-IR Schimadzo ST EQ-025 
12 Digital  tablet  dissolution
apparatus,  USP
Electrolab,  TDT – O8L  Mumbai
13 Mechanical stirrer Remi motors ltd,  RQT – 124A,  Mumbai
14 Moisture Analyzer Sartorius,  MA – 100
15 UV/Visible spectrophotometer Shimadzu,  A11454783115
16 pH meter Electrolab,  Mumbai
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EXPERIMENTAL PROCEDURE:
DRUG – EXCIPIENT COMPATIBILITY STUDIES:                                                           
Drug  instability  is  the  loss  of  drug  through chemical  and  physical  degradation  resulting
in a reduction potency. To investigate the possible interaction between Aceclofenac and the
excipients used in the formulations and to check the physical appearance of the product.  The
accurately  weighed  amount  of  drug  and  the  excipient  are  kept  into  vial  for  30days  at
40°±2/75±5% RH 1 month. To check the physical appearance of the drug-excipient whether
it is compatible.
 DIFFERENTIAL SCANNING CALORIMETRY STUDIES (DSC):
In order to investigate the possible interaction between Aceclofenac, Eudragit S100, HPMCP,
differential scanning calorimetry (DSC) analysis was carried out on pure substances and their
physical  mixtures  (PM)  in  equimolar  ratios  using  the  Perkin  Elmer  Thermal  Analyzer
instrument equipped with a computerized data section. Samples (3 to 4 mg) were placed in an
⁰aluminium pan and heated at  a  rate  of  10 c/min with indium in the reference pan in an
⁰atmosphere of nitrogen at a rate of 50.ml/min to a temperature of 200 c. 
DRUG – EXCIPIENT INTERACTION STUDIES (FT-IR):
Infrared spectroscopy is one of the analytical technique for the determination of presence of
various  functional  groups  involved  in  making  up  the  molecule.  It  provides  very  well
accountable spectral data regarding any change in the functional group characteristics of a
drug molecule occurring in the process of formulation. IR spectra of Aceclofenac and its
formulations were obtained by Potassium bromide pellet method using FT-IR Schimadzo ST
EQ-025 Spectrophotometer in order to find out drug-carrier interaction occurring during the
formulation process. 
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EVALUATION TESTS:
PREFORMULATION EVALUATION TESTS
Determination of Bulk density and Tapped density:
An accurately weighed quantity of the powder (W), was poured into the graduated cylinder
and the volume (V0) was measured. Then the graduated cylinder was closed with lid, set into
the density determination apparatus. The density apparatus was set for 100 taps and after that,
the volume (Vf) was measured and operation was continued till the two consecutive readings
were equal. The bulk density and tapped density were calculated using the following formula:
Bulk density = W / V0
            
Tapped density = W / Vf
Where, W = Weight of the powder V0 = Initial volume Vf = Final volume
Compressibility Index or Carr’s Index (CI):
It indicates the ease with which a material can be induced to flow. The Compressibility Index
(Carr’s Index) is a measure of the propensity of a powder to be compressed. It is determined
from the bulk and tapped densities. the less compressible a material, the more flowable it is.
It is a measure of the relative importance of inter-particulate interactions. In a free-flowing
powder, such interactions are generally less significant and the bulk, tapped densities will be
closer  in  value.  For  poor  flowing  materials,  there  are  frequently  greater  inter-particle
interactions and a greater difference between the bulk and tapped densities will be observed.
These differences are reflected in the Compressibility Index which is calculated using the
following formula:
 (Dt – Db) 
     CI = x 100
      Dt
Where,       Dt = Tapped density of the powder.
       Db = Bulk density of the powder.
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Hausner’s Ratio:
Hausner’s ratio was measured by the ratio of tapped density to bulk density.
Hausner’s ratio = Tapped density / Bulk density
Table 9: Carr’s Index and Hausner’s Ratio values
Compressibility Index Flow character Hausner Ratio
< 10
11 – 15
16 – 20
21 – 25
26 – 31
32 – 37
> 38
Excellent
Good
Fair
Passable
Poor
Very poor
Very, Very poor
1.00 – 1.11
1.12 – 1.18
1.19 – 1.25
1.26 – 1.34
1.35 – 1.45
1.46 – 1.59
> 1.60
Angle of Repose (θ):
The frictional forces in a loose powder can be measured by angle of repose,  θ. This is the
maximum angle possible between the surface of a pile of powder and the horizontal plane.
The powder mixture was allowed to flow through the funnel fixed to a stand at  definite
height. The angle of repose was then calculated by measuring the height and radius of the
heap of the powder formed.
The fixed funnel method was employed to measure the angle of repose. A funnel was secured
with its tip at  a given height (h),  above a graph paper that is  placed on a flat  horizontal
surface. The blend was carefully poured through the funnel until the apex of the conical pile
just touches the tip of the funnel. The radius (r) of the base of the conical pile was measured.
The angle of repose (θ) was calculated using the following formula:
θ = tan-1(h/r)
Where, θ = angle of repose, h = height of the pile in cms, r = radius of the pile.
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COMPRESSION OF TABLET:
After  Preformulation  studies,  the  blend  was  subjected  to  compression  using  Cadmach
16-station machine and 7.5 mm diameter round standard concave punch. The hardness was
maintained between 5-6 kg/cm2 as the tablets were intended for controlled release and the
tablets were subjected to the following post formulation evaluation tests.
POST FORMULATION EVALUATION TEST OF THE TABLETS
Hardness:
Hardness of the tablet is defined as the force applied across the diameter of the tablet in the
order to break the tablet. The resistance of the tablet to chipping, abrasion or breakage under
condition of storage transformation and handling before usage depends on its hardness. For
each formulation, the hardness of 6 tablets was determined using a Varian ,VK 200 .hardness
tester. It is expressed in Kg / cm2. 
Friability (F):
It is a measure of mechanical strength of tablets. The friability of the tablet was determined
using Electro lab EF-2,  friabilator  (USP).  It  is  expressed  in  percentage (%).It  should be
preferably between o.5 to 1.0%. 10 tablets were initially weighed (Winitial) and transferred into
the friabilator. The friabilator was operated at 25 rpm for four mins. The tablets were weighed
again (Wfinal). The percentage friability was then calculated by:
W initial – W final
F =     x 100
       W initial
Weight Variation:
Twenty  tablets  were  selected  randomly  and  weighed  individually  to  check  the  weight
variation. IP limit for weight variation in case of tablets weighing up to 80 mg is ± 10%.
%Deviation = (Individual weight – Average weight / Average weight) x 100
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            Table 10: Pharmacopoeial specifications for tablet weight variation
Average weight of
Tablets (mg) (I.P)
Average weight of
Tablets (mg) (U.S.P)
Maximum percentage
difference allowed
Less than 80
80 – 250
More than 250
Less than 130
130 – 324
More than 324
10
7.5
5
Thickness:
Tablet thickness is an important characteristic in reproducing appearance. Twenty tablets 
were taken and their thickness was measured by Digimatic vernier callipers. It is expressed in
the form of   mm. 
Content Uniformity:
 Powder the tablets and weigh the powder equivalent to 100 mg of Aceclofenac  taken
in100 ml volumetric flask.
  Make up to 100 ml with methanol.
  Pipette out 2 ml into 100 ml flask and make up to 100 ml with methanol (20 ppm). 
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Construction of standard calibration curve of Aceclofenac:
Preparation of 7.4 pH Phosphate buffer:
7.4 pH phosphate buffer was prepared by taking 6.8 g of  Potassium dihydrogen phosphate 
was accurately weighed and transferred into 1 litre volumetric flask and the volume was 
made up to 1 litre with distilled water and the pH is adjusted to 7.4 using sodium hydroxide 
solution.
Preparation of Standard Stock Solution:
22.4  mg  of  Aceclofenac  standard  was  accurately  weighed  and  transferred  into  100  ml
volumetric flask and the volume was made up to 100 ml with methanol.
Preparation of working standard solution:
 5 ml of stock solution was pipetted into 100 ml volumetric flask and the volume was 
made up to 100 ml with 7.4 pH Phosphate buffer.
 7.5 ml of stock solution was pipetted into 100 ml volumetric flask and the volume was
made up to 100 ml with 7.4 pH Phosphate buffer.
 5 ml of stock solution was pipetted into 50 ml volumetric flask and the volume was 
made up to 50 ml with 7.4 pH Phosphate buffer.
 6.25 ml of stock solution was pipetted into 100 ml volumetric flask and the volume 
was made up to 50 ml with 7.4 pH Phosphate buffer.
 7.5 ml of stock solution was pipetted into 100 ml volumetric flask and the volume was
made up to 50 ml with 7.4 pH Phosphate buffer.
Preparation of Aceclofenac Tablets (F1-F5):
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 The formulation consists of active moiety Aceclofenac, microcrystalline cellulose as directly
compressible  diluents,  croscarmellose  sodium as  disintegrating agent,  talc  as  glidant  and
magnesium stearate as lubricant. The drug, microcrystalline cellulose ,Eudragit S-100 were
passed  through  40#  size  mesh  separately  prior  to  the  preparation  of  the  dosage  form.
Accurately weighed amount of drug, microcrystalline cellulose were mixed thoroughly for 10
min to ensure uniform mixing in geometrical ratio in Kalaweka blender . The obtained blend
was subjected to granulation using Eudragit S100 dissolved in sufficient quantity of Isopropyl
⁰alcohol as binder. The obtained granules were subjected to drying in a dryer at 60 c for 1
hour.  The  dried  granules  are  then  passed  through  20#  size  mesh  and  then  mixed  with
magnesium  stearate,  talc  passed  through  60#  size  mesh.  The  obtained  blend  was  then
subjected to preformulation studies.
 Table 11: Formulation of Aceclofenac tablets (F1 –F5): 
S.NO Ingredients F1(mg/tab
)
F2(mg/tab
)
F3(mg/tab) F4(mg/tab
)
F5(mg/tab
)
1 Aceclofenac 100 100 100 100 100
2 MCC 17.60 22.60 27.60 32.60 37.60
3 Eudragit S100 40.00 35.00 30.00 25.00 20.00
4 IPA Q.S Q.S Q.S Q.S Q.S
5 Talc 1.60 1.60 1.60 1.60 1.60
6 Magnesium stearate 0.80 0.80 0.80 0.80 0.80
7 Core Tablet  weight 160.00 160.00 160.00 160.00 160.00
Determination of λmax of Aceclofenac in 0.1 N Hcl:
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Preparation of Simulated gastric fluid (0.1 N Hcl ):  8.5 ml of concentrated hydrochloric
acid was added in 1 litre volumetric flask and then volume was made up to 1 litre with
distilled water and the pH was adjusted to 1.2 with concentrated hydrochloric acid.
Preparation of Standard Stock Solution:
22.4  mg  of  Aceclofenac  standard  was  accurately  weighed  and  transferred  into  100  ml
volumetric flask and the volume was made up to 100 ml with methanol .
Preparation of working standard solution:
 5 ml of stock solution was pipetted into 100 ml volumetric flask and the volume was 
made up to 100 ml with 0.1 N Hcl.
Scanning range: 200 – 300 nm
 Determination of λMax of Aceclofenac in 6.8 pH phosphate buffer:
Preparation of (6.8 pH phosphate buffer):
6.8 g of Potassium dihydrogen phosphate was accurately weighed and transferred into 1 litre 
volumetric flask and the volume was made up to 1 litre with distilled water and the pH is 
adjusted to 6.8 using sodium hydroxide solution.
Preparation of Standard Stock Solution:
22.4  mg  of  Aceclofenac  standard  was  accurately  weighed  and  transferred  into  100  ml
volumetric flask and the volume was made up to 100 ml with methanol.
Preparation of  standard solution :
5 ml of stock solution was pipetted into 100 ml volumetric flask and the volume was made up
to 100 ml with 6.8 pH phosphate buffer.
Scanning  range : 200 – 300 nm
Determination of λmax of Aceclofenac in 7.4 pH phosphate buffer:
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Preparation of (7.4 pH phosphate buffer):
6.8 g of  Potassium dihydrogen phosphate was accurately weighed and transferred into 1 litre 
volumetric flask and the volume was made up to 1 litre with distilled water and the pH is 
adjusted to 7.4 using sodium hydroxide solution.
Preparation of Standard Stock Solution:
22.4  mg  of  Aceclofenac  standard  was  accurately  weighed  and  transferred  into  100  ml
volumetric flask and the volume was made up to 100 ml with methanol.
Preparation of working standard solution:
5 ml of stock solution was pipetted into 100 ml volumetric flask and the volume was made up
to 100 ml with 7.4 pH phosphate buffer.
Scanning range: 200 – 300 nm
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Dissolution profile of the tablets:
 Dissolution of Aceclofenac tablets was studied using USP  type 2 (paddle) dissolution test
apparatus Digital tablet dissolution apparatus, Electrolab, TDT – O8L employing paddle
as a stirrer in 900 ml of 0.1 N Hcl (1.2 pH) for 2 hours.
  It is carried out in 6.8 pH phosphate buffer for 3 hours and 7.4 pH phosphate buffer for
12 hours. 
 ⁰ The  stirrer  was  adjusted  to  rotate  at  75  rpm  and  a  temperature  of  37±0.5 c  was
maintained throughout the experiment. 
5 ml of samples were withdrawn at various time intervals and analyzed for Aceclofenac by
measuring  the  absorbance  at  276  nm.  The  volume  withdrawn  at  various  intervals  was
immediately replaced with fresh quantity of dissolution medium.
Stability studies:
 The optimized formulation were subjected to stability studies at  40⁰C ±2 / 75%±5 RH for
1month .
 The product was evaluated for the physical characteristics, drug content and In vitro  drug
release profile over a period of 1month
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Table 12: DRUG – EXCIPIENT COMPATIBILITY STUDIES: 
S.No Ingredients mg/tab Drug excipient
ratio
Observation
Initial
40±2°c/75±5%R
H
After 1- Month
1 Aceclofenac 100 - White granularpowder
No characteristic
change
2 MCC 16 1  : 0.16 White granularpowder
No characteristic
change
3 Eudragit S100 40 1 : 0.4 White granularpowder
No characteristic
change
4 Talc 1.6 1: 0.016 White granularpowder
No characteristic
change
5 Magnesium stearate 0.8 1: 0.008 White granularpowder
No characteristic
change
DIFFERENTIAL SCANNING CALORIMETRY (DSC) STUDIES: 
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 Figure 6: DSC of Pure drug Aceclofenac:
Figure 7: DSC of polymer Eudragit S100
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Figure 8: DSC of Aceclofenac and Eudragit S100
 Table 13: Data obtained from DSC Curves:
S.No Name of the substance Peak Integration
1 Aceclofenac Onset – 151.96⁰C.,Maximum – 
153.96⁰C., Stop – 159.94⁰C
2 Eudragit S-100 No results to report 
3 Aceclofenac + Eudragit S-100 Onset – 150.43⁰C., Maximum – 
152.93⁰C., Stop – 158.31⁰C
DRUG – EXCIPIENT INTERACTION STUDIES (FT-IR): 
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Figure 9: FT-IR of Pure Aceclofenac
                              Figure 10: FT-IR of Aceclofenac & final (F-4):
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Figure 11: Comparision of FT-IR of Pure Aceclofenac and its final (F-4):
     
Table 14: Evaluation of Pre-formulation parameters of Aceclofenac tablet F1-F5:
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Formulatio
n Code
Angle of Repose
± S.D
Bulk
Density
Tapped
Density
% Carr’s
Index
Hausner’
s ratio
F1 30.32 ± 0.33 0.332 0.412 19.417 1.24
F2 32.07 ± 0.66 0.344 0.436 21.100 1.26
F3 30.12 ± 0.33 0.365 0.469 22.174 1.26
F4 29.33±0.33 0.323 0.398 18.844 1.23
F5 27.32 ± 0.14 0.325 0.405 19.753 1.24
Table 15: Evaluation of Post-Compression parameters of Aceclofenac tablets:
Formulation
Code
Hardness
(kg/cm2)
Average
weight of 20
tablets (mg)
Friability
(%)
Thickness
(mm)
Drug Content
± S.D (%)
F1 5.5 163.3 ± 0.33 0.38 3.2 100.6 ± 0.74
F2 5.0 160.5 ± 0.35 0.45 3.2 99.9 ± 0.70
F3 5.0 162.0 ± 0.25 0.58 3.2 97.2 ± 0.28
F4 5.5 160.4 ± 0.56 0.64 3.2 98.6 ± 0.61
F5 6.0 161.5 ± 0.64 0.54 3.2 99.3 ± 0.58
*Average of three determinations.
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Table 16:  Calibration and absorbance values of Aceclofenac in 7.4 pH phosphate buffer
at 276 nm: 
S.No Concentration (mcg) Absorbance (nm)
1 0 0
2 0.0112 0.277
3 0.0168 0.419
4 0.0224 0.553
5 0.0280 0.693
6 0.0336 0.830
Figure  12:   Standard  Calibration  curve  of  Aceclofenac  in  7.4  pH Phosphate
buffer: 
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Table 17: Determination of λmax of Aceclofenac in 0.1 N Hcl: 
S.No Wavelength(nm) Absorbance
1 250.0 0.0260
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2 255.0 0.0290
3 260.0 0.0393
4 265.0 0.0534
5 270.0 0.0664
6 275.0 0.0695
7 280.0 0.0569
8 285.0 0.0268
9 290.0 0.0085
 
Figure 13: Determination of λmax of Aceclofenac in 0.1 N Hcl: 
  Table 18: Determination of λmax of Aceclofenac in 6.8 pH phosphate buffer: 
S.No Wavelength(nm) Absorbance
1 250.0 0.0162
2 255.0 0.0193
3 260.0 0.0253
4 265.0 0.0434
5 270.0 0.0557
6 275.0 0.0595
k.k college of pharmacy  Page 61
                                                                                                                 Results
7 280.0 0.0462
8 285.0 0.0154
 Figure 14: Determination of λmax of Aceclofenac in 6.8 pH phosphate buffer:
Table 19: Determination of λmax of Aceclofenac in 7.4 pH phosphate buffer:
S.No Wavelength (nm) Absorbance
1 271.0 0.645
2 272.0 0.659
3 273.0 0.666
4 274.0 0.669
5 275.0 0.671
6 276.0 0.671
7 277.0 0.669
8 278.0 0.664
9 279.0 0.654
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                      10 280.0 0.648
Figure 15: Determination of λmax of Aceclofenac in 7.4 pH phosphate buffer: 
Dissolution profile of (F1-F5) formulation:
Table 20: In vitro drug release of Aceclofenac (F1-F5) in pH 7.4 phosphate buffer.
S.No Time
(hrs)
F1 F2 F3 F4 F5
%drug
released ±
SD
%drug
released ±
SD
%drug
released ±
SD
%drug
released ±
SD
%drug
released ±
SD
1. 01 3.16 ± 0.056 4.41 ± 0.045 5.98 ± 0.063 8.32 ± 0.025 6.51 ± 0.045
2. 02 15.62 ± 0.22 18.63 ± 0.065 19.24 ± 0.045 24.63 ± 0.066 22.34 ± 0.099
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3. 04 22.73 ± 0.45 25.21 ± 0.23 27.45 ± 0.45 31.62 ± 0.26 29.46 ± 0.45
4. 06 29.47 ± 0.54 33.23 ± 0.65 37.82 ± 0.52 48.41 ± 0.57 44.43 ± 0.35
5. 08 45.36 ± 0.35 49.12 ± 0.69 53.51 ± 0.52 64.23 ± 0.89 59.17 ± 0.48
6. 10 61.97 ± 0.66 66.52 ± 0.54 69.15 ± 0.63 81.62 ± 0.55 72.53 ± 0.63
7. 12 75.91 ± 0.62 79.48 ± 0.78 82.18 ± 0.36 94.32 ± 0.65 89.36 ± 0.85
Figure 16:  In vitro drug release of Aceclofenac (F1 – F5):
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Stability studies:
Table 21:  Stability study of Aceclofenac formulation (F4) at 40±2⁰C/75±5%RH :
S.No. Time in days Physical changes % Drug Content ± SD
(40±2⁰C/75±5%RH)
1. 01 -- 98.64 ± 0.82
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2. 10 No change 98.00 ± 0.30
3. 20 No change 97.35 ± 0.51
4. 30 No change 97.09 ± 0.40
Table 22:  In vitro % drug Release of Aceclofenac (F4) after1month placing in stability
chamber:
S.No. Time (hrs) Cumulative % Drug Released ± SD   at
40±2⁰C/75±5%RH
1st Day 30th Day
1. 01 8.32 ± 0.025 8.19 ± 0.20
2. 02 24.63 ± 0.066 23.34 ± 0.60
3. 04 31.62 ± 0.26 29.27 ± 0.22
4. 06 48.41 ± 0.57 47.35 ± 0.99
5. 08 64.23 ± 0.89 65.19 ± 0.81
6. 10 81.62 ± 0.55 80.26 ± 0.12
7. 12 94.32 ± 0.65 93.34 ± 0.24
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DISCUSSION
The drug and the excipients compatibility studies shows there is no physical characteristic
change shown in Table -12
The DSC trace of Aceclofenac shows five endothermic peaks at 153.96⁰C, 152.93⁰C. as
shown in Figure no : 6 - 8. The first peak is associated with the melting of Aceclofenac
(reported m.p is  149 - 153⁰C). The second peak showed no drastic changes from the
melting point of the pure drug. The polymer did not show any characteristic endotherms.
This is attributed to evaporation of absorbed water from the polymer during heating. So,
Aceclofenac is chemically compatible with the polymers as shown in Table-13.
The IR spectrum of Pure Aceclofenac and its formulation (F4) were found to be similar to
the peaks of both the spectrums are matching. IR studies have no interaction between
drug and excipients as shown in Figures 9 – 11.
The apparent bulk density and tapped bulk density values ranges from 0.323 to 0.365 g/cc
and 0.398 to 0.469 g/cc respectively. The results of angle of repose and compressibility
index (%) ranges from 27.32 ±0.33 to 32.07±0.66 and 18.844 to 22.174 respectively. And
the moisture content  shows less than 1% in all  formulations.  The results  of  angle of
repose (<35) and compressibility index (<23) indicates fair to passable flow properties of
the powder mixture as shown in table-14.
The hardness of the tablet (F1-F5) was found to be in the range of 5 – 6 kg/cm2 as shown
in  Table-15.  The friability values were found to be in the range of 0.34 to 0.78% as
shown in Table-15.
All the prepared tablets of Aceclofenac were evaluated for weight variation. The weight
of all  the tablets was found to be uniform with low values of standard deviation and
within the prescribed IP limits of ±7.5% as shown in Table-15.
The low values of standard deviation includes uniform drug content within the tablets.
The percent drug content of all the tablets was found to be in the range of 97.2 to 100.6 %
as shown in Table-15.
k.k college of pharmacy  Page 67
                                                                                                           Discussion
The standard graph of Aceclofenac in pH 7.4 showed good linearity. The λmax of Aceclofenac
was determined in pH 1.2, pH 6.8, pH 7.4 and was found to be 276 nm.
The  release  of  Aceclofenac  from  the  different  formulations  was  measured  using  UV-
spectrophotometer.  In  pH 7.4  phosphate  buffer  formulation  F-4  showed  drug  release  of
94.32 %   at the end of 12 hours has shown in Table 20. So formulation F4 has been selected
as the best formulation and it was taken for stability studies.
 Stability studies was carried on the best formulation F-4 at 40⁰C±2 / 75%±5 RH for 1month.
It showed no significant changes in physical appearance, drug content and in vitro dissolution
as shown in Tables- 21-22.
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SUMMARY 
In the present research work, the colon-targeting tablets of Aceclofenac were prepared by wet
granulation.  Formulation  F1-F5 were  formulated  by taking drug-excipient  in  the  ratio  of
Aceclofenac, MCC,  Eudragit S100, Talc, Magnesium stearate.1:1, 1 : 0.16, 1 : 0.4, 1: 0.016, 1:
0.008 Respectively .The pure drug and the excipients were subjected to compatibility studies
by  DSC  and  FT-IR  IR  spectroscopic  studies  indicated  that  there  are  no  drug-excipient
interactions. DSC obtained showed no drug-polymer interaction. 
All the tablets were subjected to pre- formulation evaluation studies by bulk density, tapped
density, carr’s index, hausner’s ratio and angle of repose.  The tablets are compressed and
subjected to post formulation evaluation test.
Tablets prepared by wet granulation method were found to be good without any tabletting
problems such as chipping,  capping,  sticking and lamination. Hardness,  friability ,weight
variation,  thickness  ,drug  content  uniformity were  evaluated  and  found  to  be  within  the
limits.  The  standard  graph  of  pure  drug  Aceclofenac  in  pH  7.4  phosphate  buffer  was
constructed and a linear graph was obtained.
From the in vitro dissolution studies carried in pH 7.4 phosphate buffer formulation F-4 was
found to show retardation of drug release when compared F-1,F-2,F-3 and F-5 formulations.
Hence F-4 was selected as the best formulation for colon drug delivery and it was subjected
to stability studies.
 Accelerated  stability  studies  of  F-4  formulation  conducted  according  to  ICH  guidelines
indicated  that  there  are  no  significant  changes  in  drug-  content  and  in  vitro dissolution
release.
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Aceclofenac  is  a  non-steroidal  anti-  inflammatory drug and  analgesic  which  used  in  the
treatment  of  rheumatoid  arthritis,  Osteoarthritis,  ulcerative  colitis.  Its  usual  dose  is
100mg for 1 time. It causes gastric irritation when taken in morning. So an attempt has been
done to formulate and evaluate Aceclofenac tablets to release the drug specifically to the
colon  by  using  a  pH  dependent  polymer  Eudragit  S100  at  pH  7.4  by  wet  granulation
technique. This attempt was successful by formulation F-4 which was capable of releasing
94.32% in 12 hrs. Long-term stability studies have to be done for the formulation.  In vivo
studies have to be performed to conform the studies  on Aceclofenac colon specific  drug
delivery systems
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